# Colorectal cancer trials open today (registry snapshot)

Source: https://onco.cc/terms/colorectal-trials-open-today/  
OnCo record `colorectal-trials-open-today` (Term). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Every phase 2 or 3 interventional trial that was recruiting, about to open or still running for colorectal, colon or rectal cancer on ClinicalTrials.gov in September 2026, with the hospitals in the United Kingdom that take part named where the registry lists them.

## Summary

The ClinicalTrials.gov v2 API was searched on 24 September 2026 for interventional phase 2, 1/2, 2/3 and 3 studies naming colorectal, colon or rectal cancer that were recruiting, not yet recruiting, enrolling by invitation or (for phase 3 and 2/3) active but closed to recruitment. Trials already in the corpus, and trials whose only bowel involvement is an anal, appendiceal, small-bowel or neuroendocrine condition, are left out; the remainder are carried here as registry-only records with no outcomes, because a trial that has not reported has no result to quote. Records link to the subtype page the registry text names (colon, rectum, MSI-high, BRAF V600E, HER2-amplified, KRAS G12C, early onset) and to `colorectal` itself only when it names none, so the cancer page stays under its markup ceiling. UK sites are quoted verbatim in each record's notes. The questions open today divide into four: whether circulating tumour DNA should choose who gets chemotherapy after surgery, whether the rectum can be kept after chemoradiotherapy or immunotherapy, whether targeted combinations (KRAS G12C, BRAF, HER2, RAS(ON)) belong in first-line treatment, and whether anything can make microsatellite-stable disease respond to immunotherapy.

## Fields

- Kind: Term
- Last checked: 2026-09-24
- Also known as: Bowel cancer trials recruiting; Open colorectal cancer trials

## Sources

- ClinicalTrials.gov search: colorectal cancer, interventional, phase 2 and 3: https://clinicaltrials.gov/search?cond=colorectal%20cancer&aggFilters=phase:2%203,studyType:int

## Connected records

- cancers: [Colorectal cancer](https://onco.cc/cancers/colorectal/)
- technologies: [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/), [KRAS & RAS inhibitors](https://onco.cc/technologies/kras-inhibitors/), [MRD / molecular residual disease testing](https://onco.cc/technologies/mrd-testing/)
- terms: [Clinical complete response (cCR)](https://onco.cc/terms/clinical-complete-response/), [Minimal / molecular residual disease (MRD)](https://onco.cc/terms/mrd/), [Total neoadjuvant therapy (TNT, rectal cancer)](https://onco.cc/terms/total-neoadjuvant-therapy/)
- trials: [- IKF/AIO-QUINTIS - Evaluating Fruquintinib in Combination With Tislelizumab in Microsatellite Stable / Proficient Mismatch Repair (MSS/pMMR) Metastatic Colorec](https://onco.cc/trials/nct06856837/), ["Thymalfasin Immunotherapy Study with Triple Regimen in Advanced MSS/pMMR Colorectal Cancer"](https://onco.cc/trials/nct06829355/), [125I Seed Implantation Plus Systemic Therapy for Oligoprogressive NSCLC or Colorectal Cancer](https://onco.cc/trials/nct07333651/), [16-Hour Fasting Plus Serplulimab and CAPEOX as Neoadjuvant Therapy in pMMR/MSS Advanced Mid-to-Low Rectal Cancer](https://onco.cc/trials/nct07779694/), [5-fluorouracil Plus Panitumumab (Anti-EGFR) and Sotorasib (KRAS G12C Inhibitor) in First-line Treatment of Patients Non-eligible for a Doublet/Triplet Chemother](https://onco.cc/trials/nct07124884/), [5-Fluorouracil/Leucovorin (5FU/LV) in Combination With Regorafenib in Patients With Metastatic Colorectal Cancer](https://onco.cc/trials/nct06887218/), [5FU/LV, Irinotecan, Temozolomide and Bevacizumab for MGMT Silenced, Microsatellite Stable Metastatic Colorectal Cancer.](https://onco.cc/trials/nct04689347/), [A Clinical Study of Iparomlimab and Tuvonralimab Combined With Fruquintinib and Heterogeneous Radiotherapy Versus Fruquintinib as Third-Line and Subsequent-Line](https://onco.cc/trials/nct07502014/), [A Clinical Study of Liposomal Irinotecan for Second-Line Therapy in Metastatic Colorectal Cancer](https://onco.cc/trials/nct07585279/), [A Clinical Study on the Efficacy and Safety of Fruquintinib in Combination With PD-1 Monoclonal Antibody and Chidamide in Refractory MSS Metastatic Colorectal C](https://onco.cc/trials/nct06979908/), [A Clinical Study on the Treatment of Metastatic Colorectal Cancer at the Second-line or Beyond.](https://onco.cc/trials/nct07395063/), [A Clinical Study to Evaluate Injection TQB2102 for the Treatment of Patients With HER2 IHC3+ Advanced Colorectal Cancer Who Progressed After Treatment With Oxal](https://onco.cc/trials/nct07483684/), [A Clinical Study to Evaluate the Efficacy and Safety of Envafolimab Combined With Cetuxima-βand mFOLFOX6 in Patients With MSS, RAS/BRAF Wild-Type Metastatic Col](https://onco.cc/trials/nct06959693/), [A Clinical Trial Comparing Long-Course Versus Short-Course Radiotherapy Followed by Immunotherapy Combined With Total Neoadjuvant Therapy (TNT) to Long-Course R](https://onco.cc/trials/nct07113275/), [A Clinical Trial Evaluating TQB2930 Injection and Chemotherapy With or Without Bevacizumab in Patients With HER2-Abnormally Expressed Unresectable Locally Advan](https://onco.cc/trials/nct07653685/), [A Clinical Trial of LBL-024 Combination Drug in Patients With Metastatic Colorectal Carcinoma](https://onco.cc/trials/nct07791758/), [A Combination Therapy Including Anti-PD-1 Immunotherapy in MSS Rectal Cancer With Resectable Distal Metastasis](https://onco.cc/trials/nct05359393/), [A Global Trial of Trastuzumab Rezetecan (SHR-A1811) in Combination With Chemotherapy and Bevacizumab as First-Line Treatment in Patients With Advanced Colorecta](https://onco.cc/trials/nct07796763/), [A Multicenter Phase 1b/2 Study of Adagrasib, Cetuximab, and Cemiplimab for Metastatic Colorectal Cancer Harboring KRAS G12C Mutations](https://onco.cc/trials/nct06412198/), [A Multicenter Single-arm P2 to Evaluate Safety and Efficacy of the Total Neoadjuvant Therapy for cT2 Rectal Cancer](https://onco.cc/trials/nct05939661/), [A Multicenter Study of Active Specific Immunotherapy With OncoVax® in Patients With Stage II Colon Cancer](https://onco.cc/trials/nct02448173/), [A Multicenter, Open Phase IIb Clinical Study to Evaluate the Efficacy and Safety of B1962 Injection in the Treatment of Advanced Colorectal Cancer](https://onco.cc/trials/nct06838546/), [A Multicenter, Phase Ib/II Clinical Trial to Evaluate the Efficacy and Safety of Concurrent Combination Therapy of S-531011 Plus Fruquintinib or S-531011 Plus F](https://onco.cc/trials/nct07591597/), [A Multicenter, Randomized Controlled Phase II Study of Short-Course Radiotherapy Followed by Sequential PD-1 Inhibitor and FOLFOX Chemotherapy Versus Long-Cours](https://onco.cc/trials/nct07669220/), [A Phase 2 Study Evaluating the Safety and Efficacy of JS207 With or Without JS015 in Combination With Chemotherapy in Patients With Colorectal Cancer](https://onco.cc/trials/nct06885385/), [A Phase I-II Study to Test the Safety and Efficacy of PD1 (AB122) and Adenosine Receptor (AB928) Antagonists With Chemotherapy After Short-Course Radiation for](https://onco.cc/trials/nct05024097/), [A Phase Ib/II Study of HDM2017 in Combination With Standard of Care in Advanced Colorectal Cancer](https://onco.cc/trials/nct07621159/), [A Phase Ib/II Study of SYS6090 Combination Therapy in Advanced Colorectal Cancer](https://onco.cc/trials/nct07750041/), [A Phase Ib/II Study to Evaluate HLX43 Combined With HLX07 or Serplulimab in Patients With Advanced or Metastatic Colorectal Cancer](https://onco.cc/trials/nct07358585/), [A Phase II Clinical Study of Aipalolitovorelizumab (QL1706) Combined With Fruquintinib in the Treatment of Immunodominant pMMR/MSS Metastatic Colorectal Cancer](https://onco.cc/trials/nct07229872/), [A Phase II Clinical Study of the Efficacy and Safety of Tislelizumab Combined With Fruquintinib and Chidamide in the Treatment of Unresectable or Advanced Micro](https://onco.cc/trials/nct06218888/), [A Phase II Platform Study to Evaluate Treatment With Cemiplimab Monotherapy or Cemiplimab Plus Fianlimab or Other Novel Combinations in Patients With Colorectal](https://onco.cc/trials/nct07058012/), [A Phase II Prospective Study of Maastro Applicator Brachytherapy for Rectal Cancer](https://onco.cc/trials/nct07402486/), [A Phase II Randomized Trial of Serplulimab With Second-Line Chemo/Targeted Therapy for Early Relapse Colorectal Cancer After Adjuvant Chemotherapy](https://onco.cc/trials/nct07604909/), [A Phase II Single-Arm Study of High-Bioavailability Curcumin as Neoadjuvant Chemoradiotherapy in Mid-to-Low Rectal Cancer: Integrated Clinical and Translational](https://onco.cc/trials/nct07248020/), [A Phase II Study of Pirfenidone Plus PD-1 Inhibitor With or Without Hypofractionated Radiotherapy for Refractory pMMR/MSS Colorectal Cancer](https://onco.cc/trials/nct07644286/), [A Phase II Study of Sintilimab Combined With Ipilimumab N01, Cetuximab and Dabrafenib in Patients With Microsatellite-Stable, BRAF V600E-Mutated Metastatic Colo](https://onco.cc/trials/nct07506109/), [A Phase II Study of Tislelizumab as Adjuvant Therapy for Patients With Stage II and Stage III Colon Cancer and dMMR/MSI.](https://onco.cc/trials/nct05231850/), [A Phase IIa Randomized, Double-Blinded Clinical Trial of Naproxen or Aspirin for Cancer Immune Interception in Lynch Syndrome](https://onco.cc/trials/nct05411718/), [A Phase ll Study of Neoadjuvant Short-course Radiotherapy Followed by Ivonescimab and Chemotherapy in pMMR/MSS Locally Advanced Rectal Cancer](https://onco.cc/trials/nct06919510/), [A Pilot Study Evaluating β-hydroxybutyrate Supplementation Concomitant to Short-Course Radiotherapy Followed by Immunotherapy Combined With CAPEOX Neoadjuvant T](https://onco.cc/trials/nct07239466/), [A Prospective Multicenter Study: Ivosimab + Chemotherapy as Neoadjuvant for Resectable pMMR/MSS CRC Liver Mets](https://onco.cc/trials/nct06972498/), [A Prospective Study of MSS-type Metastatic Colorectal Cancer Receiving Multiple Lines of Standard Chemotherapy, Bevacizumab Combined With Adebrelimab](https://onco.cc/trials/nct06513221/), [A Prospective, Multicenter, Single-Arm Phase II Exploratory Study of Serplulimab Combined With Oncolytic Virus H101, Short-Course Radiotherapy, and XELOX Chemot](https://onco.cc/trials/nct07543848/), [A Prospective, Open-label, Single-arm Phase II Clinical Study of Fruquintinib Combined With S-1 for the Treatment of Metastatic Colorectal Cancer.](https://onco.cc/trials/nct06746545/), [A Randomized Controlled Trial of Plasma ctDNA Methylation-Guided Adjuvant Chemotherapy Decision-Making in High-Risk Stage III (T4N+ or T1-3N2) Colorectal Cancer](https://onco.cc/trials/nct07562490/), [A Randomized Phase III Study Comparing Maintenance Treatment With Fluoropyrimidine + Bevacizumab Versus Fluoropyrimidine After Induction Chemotherapy for a Meta](https://onco.cc/trials/nct04188145/), [A Series of Neoadjuvant Chemoradiotherapy Combined With Immunotherapy for Locally Advanced Rectal Cancer](https://onco.cc/trials/nct06312982/), [A Single-arm Clinical Study Evaluating Pirfenidone and Sintilimab in Combination With Standard Neoadjuvant Chemotherapy for Colorectal Cancer Patients With Peri](https://onco.cc/trials/nct07268677/), [A Single-arm Phase II Clinical Study of Camrelizumab Combined With Long-course Chemoradiotherapy for Total Neoadjuvant Therapy in Locally Advanced Low pMMR/MSS](https://onco.cc/trials/nct07527026/), [A Single-arm, Multicenter Clinical Study of Fruquintinib Combined With Serplulimab and Chemotherapy as First-line Treatment for Patients With RAS/BRAF-mutated A](https://onco.cc/trials/nct07622550/), [A Single-Arm, Open-Label, Multicenter Phase I/II Clinical Study of GFH276 in Patients With RAS-Mutant Advanced Solid Tumors](https://onco.cc/trials/nct07198321/), [A Single-Arm, Phase II Study of Retlirafusp Alfa in Combination With XELOX and Bevacizumab for the First-Line Treatment of Advanced RAS-Mutated Colorectal Cance](https://onco.cc/trials/nct07797244/), [A Single-Arm, Phase II, Multicenter Clinical Study of Neoadjuvant Encorafenib Plus Cetuximab N01 and mFOLFOX6 in Patients With Locally Advanced BRAF V600E-Mutan](https://onco.cc/trials/nct07789210/), [A Single-arm, Single-center, Phase II Clinical Study of Aipalolitovorelizumab (QL1706) Combined With Bevacizumab and Standard Chemotherapy as First-line Treatme](https://onco.cc/trials/nct07229846/), [A Single-center, Phase II Study on Efficacy & Safety of SCRT+CAPOX+Serplulimab+Bevacizumab for MSS Rectal Cancer](https://onco.cc/trials/nct07347951/), [A Study Comparing BL-M07D1 With Physician's Choice Therapy in Patients With HER2 IHC3+ Advanced Colorectal Cancer Who Failed Prior Treatment With Oxaliplatin, F](https://onco.cc/trials/nct07730489/), [A Study of 2nd-line FOLFIRI ± Bevacizumab vs. Irinotecan ± Bevacizumab in mCRC](https://onco.cc/trials/nct03303495/), [A Study of AK112 in Combination With VG2025 in Colorectal Cancer With Liver Metastases](https://onco.cc/trials/nct07357220/), [A Study of Botensilimab and Balstilimab for Colorectal Cancer With ctDNA+ After Surgery and Chemotherapy](https://onco.cc/trials/nct07227636/), [A Study of Botensilimab and Balstilimab for Rectal Adenocarcinoma](https://onco.cc/trials/nct06843434/), [A Study of Cetuximabβ Combined With Envolimab and mFOLFOX6 in Subjects With Advanced Colorectal Cancer](https://onco.cc/trials/nct07000305/), [A Study of Dabrafenib Plus Cetuximab/Panitumumab With FOLFOX in the First Line of Therapy in People With Metastatic Colorectal Cancer](https://onco.cc/trials/nct06978400/), [A Study of DES-1357 in People With Deficient Mismatch Repair (dMMR)/Microsatellite Instability-High (MSI-H) Metastatic Colorectal Cancer (mCRC)](https://onco.cc/trials/nct07807800/), [A Study of Fruquintinib Plus FOLFIRI as Second-Line Treatment for Participants With Metastatic Colorectal Cancer (FRUITFUL)](https://onco.cc/trials/nct07011576/), [A Study of MRG007 Combination Therapy for Advanced Colorectal Cancer](https://onco.cc/trials/nct07737600/), [A Study of Olomorasib (LY3537982) in Participants With Advanced Colorectal Cancer and a KRAS G12C Mutation](https://onco.cc/trials/nct07814417/), [A Study of Single Fraction Stereotactic Body Radiation Therapy (SBRT) Guided by Magnetic Resonance Imaging (MRI) in People With Liver Metastasis From Colorectal](https://onco.cc/trials/nct06130280/), [A Study of the Duration of Dostarlimab in Untreated Mismatch Repair Deficient (dMMR)/ Microsatellite Instability-high (MSI-H) Locally Advanced Rectal Cancer](https://onco.cc/trials/nct07740720/), [A Study of Trastuzumab Deruxtecan (T-DXd) and Cetuximab in People With Colorectal Cancer](https://onco.cc/trials/nct07691489/), [A Study of Tucatinib and Trastuzumab in People With Rectal Cancer](https://onco.cc/trials/nct05672524/), [A Study on the Efficacy and Safety of Irinotecan Liposome (II), 5-FU/LV in Combination With Bevacizumab for the Treatment of Advanced Colorectal Cancer](https://onco.cc/trials/nct07123441/), [A Study on the Efficacy and Safety of Multi-mode Ablation Combined With Systemic Therapy in the Treatment of CRCLM](https://onco.cc/trials/nct06590259/), [A Study to Assess Safety and Efficacy of SOT109 in Patients With Advanced Unresectable or Metastatic Colorectal Cancer](https://onco.cc/trials/nct07693751/), [A Study to Characterize Encorafenib Plus Cetuximab as Rechallenge Treatment for BRAF V600E-mutant Metastatic Colorectal Cancer Patients After Previous Therapy W](https://onco.cc/trials/nct07178717/), [A Study to Evaluate INCA33890 in the Treatment of Circulating Tumor DNA-Positive Stage II/III Microsatellite Stable Colorectal Cancer After Curative Resection a](https://onco.cc/trials/nct07823322/), [A Study to Explore the Third-line Treatment of Fruquintinib Combined With Serplulimab in Advanced Non-liver-limited Metastatic Colorectal Cancer: a Single-cente](https://onco.cc/trials/nct05954429/), [A Trial of Aspirin on Recurrence and Survival in Colon Cancer Patients](https://onco.cc/trials/nct02301286/), [Abemaciclib Combined With FOLFOX/FOLFIRI Regimen in Patients With Advanced Colorectal Liver Metastases Cancer](https://onco.cc/trials/nct07441369/), [Adaptive Radiotherapy for Safe Hypofractionation](https://onco.cc/trials/nct07516210/), [Addition of Antibiotics to Upfront Treatment Regimen for Colorectal Cancer](https://onco.cc/trials/nct06728072/), [Adebrelimab Injection (PD-L1) Combined With Short Course Radiotherapy and Chemotherapy for Neoadjuvant Therapy of Locally Advanced Rectal Cancer](https://onco.cc/trials/nct06765616/), [Adjuvant Chemotherapy Combined With Targeted Therapy or Not in the T3-4N2 Colorectal Cancer Patients](https://onco.cc/trials/nct05797467/), [Adjuvant FOLFIRI Based-chemotherapy After Resection of CLM Responding to Preoperative FOLFIRI](https://onco.cc/trials/nct06501482/), [Adjuvant mFOLFIRINOX for High-risk Stage III Colon Cancer](https://onco.cc/trials/nct05179889/), [Adjuvant mFOLFOXIRI vs. mFOLFOX6 in MRD Positive Stage II-III Colorectal Cancer (AFFORD)](https://onco.cc/trials/nct05427669/), [Adjuvant PD-1 Blockade for High-risk Stage-II DMMR/MSI-H Colorectal Cancer](https://onco.cc/trials/nct06520683/), [Adjuvant Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) in Resected High Risk Colon Cancer Patients](https://onco.cc/trials/nct03280511/), [AK104 Plus Radiotherapy Combined With Standard Therapy Versus Standard Therapy as First-Line Treatment for pMMR/MSS CRLM (APSOC)](https://onco.cc/trials/nct07544784/), [AK112 Plus FOLFIRI Versus Bevacizumab Plus FOLFIRI as Second-line Treatment of MSS/pMMR Metastatic Colorectal Cancer](https://onco.cc/trials/nct07021950/), [Allogeneic NK Cell Therapy Combined With Standard Maintenance Treatment in Advanced Solid Tumors](https://onco.cc/trials/nct07551778/), [Amplitude-Modulated Radiofrequency Electromagnetic Fields (AM RF EMF) in Combination With Fruquintinib in Refractory Metastatic Colorectal Cancer](https://onco.cc/trials/nct07130903/), [An Adaptive-design Prospective Cohort Study of Watch and Wait Strategy in Patients With Locally Advanced Rectal Cancer](https://onco.cc/trials/nct04443543/), [An Explorative Study of HRS-2189 Combined With Adebrelimab and BP102 for Metastatic Colorectal Cancer](https://onco.cc/trials/nct07061210/), [An Investigational Drug (TPST-1495) in Patients With Familial Adenomatous Polyposis](https://onco.cc/trials/nct06557733/), [An Open-label, Single-arm, Multicenter Phase II Study to Evaluate the Efficacy of Amivantamab in Combination With FOLFIRI as a Second-line Treatment in Patients](https://onco.cc/trials/nct06855849/), [Anlotinib Combined With Sintilimab as First-line Treatment for Advanced Non-liver Metastatic Colorectal Cancer](https://onco.cc/trials/nct07398326/), [Antegrade Intestinal Fluid Reinfusion for Prevention of Low Anterior Resection Syndrome After Low Anterior Resection: a Single-Center, Prospective Randomized Co](https://onco.cc/trials/nct07537998/), [Anti-PCSK9 Antibody Tafolecimab and Anti-PD-1 Antibody Sintilimab Combined With Neoadjuvant Chemoradiotherapy for pMMR/ MSS Locally Advanced Rectal Cancer : A P](https://onco.cc/trials/nct07686796/), [Aspirin in Colorectal Cancer Liver Metastases](https://onco.cc/trials/nct03326791/), [ASPIRIN Trial Belgium](https://onco.cc/trials/nct03464305/), [Assess the Efficacy of Radiotherapy and Sequential Chemotherapy and AK104 Before TME Surgery for Local CRC（AK104-IIT-13）](https://onco.cc/trials/nct05794750/), [Assessing a Regorafenib-irinotecan Combination Versus Regorafenib Alone in Metastatic Colorectal Cancer Patients](https://onco.cc/trials/nct03829462/), [Assessment of Direct Biomarkers of Aspirin Action to Develop a Precision Chemoprevention Therapy of Colorectal Cancer](https://onco.cc/trials/nct03957902/), [Autologous and Allogeneic Whole Cell Cancer Vaccine for Metastatic Tumors](https://onco.cc/trials/nct00722228/), [Avapritinib for the Treatment of CKIT or PDGFRA Mutation-Positive Locally Advanced or Metastatic Malignant Solid Tumors](https://onco.cc/trials/nct04771520/), [BAL/BOT/agenT-797 in pMMR CRC With Liver Metastases](https://onco.cc/trials/nct07550088/), [Becotatug Vedotin Combined With Cetuximab in the Later-line Treatment of Metastatic RAS Wild-type Colorectal Cancer](https://onco.cc/trials/nct07490119/), [BETWEEN: Biweekly Bevacizumab + Trifluridine/Tipiracil to Reduce Grade 3-4 Neutropenia in mCRC Patients](https://onco.cc/trials/nct07071844/), [Bevacizumab Plus mFOLFOXIRI as First-line Treatment for Patients With Unresectable Metastatic Colorectal Cancer](https://onco.cc/trials/nct04230187/), [Bevacizumab-based Chemotherapy Adapted to Bevacizumab Pharmacokinetics in 1st-line Treatment](https://onco.cc/trials/nct06642844/), [Bevacizumab, Sintilimab, Cetuximab and Irinotecan in Refractory RAS Wild-type Metastatic Colorectal Cancer: BOND-4 Trial](https://onco.cc/trials/nct07722754/), [Biological Tumor Infiltrating Lymphocytes Therapy With Immunotherapy for Colon and Rectum Cancer](https://onco.cc/trials/nct06530303/), [Borderline of CME/D3 Dissection for Local Advanced Right-sided Colon Cancer](https://onco.cc/trials/nct06709144/), [Brachytherapy Followed by Nivolumab Prior to Surgery in Rectal Cancer](https://onco.cc/trials/nct07645118/), [Cabozantinib Plus Durvalumab With or Without Tremelimumab in Patients With Gastroesophageal Cancer and Other Gastrointestinal Malignancies](https://onco.cc/trials/nct03539822/), [Cadonilimab (AK104) Combined With Chemotherapy and Bevacizumab as First-line Treatment for RAS Mutated or Right Sided-metastatic MSS Colorectal Cancer](https://onco.cc/trials/nct06566755/), [Cadonilimab Combined With Fruquintinib and SBRT as Athird-line and Posterior Line Treatment in Patients With MSS CRC](https://onco.cc/trials/nct06168786/), [Cadonilimab in Combination With Bevacizumab and FOLFOX Regimen for the First-Line Treatment of Advanced Unresectable MSS-Type, RAS-Mutated Metastatic Colorectal](https://onco.cc/trials/nct06218810/), [Can we Save the Rectum by Watchful Waiting or TransAnal Surgery Following (Chemo)Radiotherapy Versus Total Mesorectal Excision for Early REctal Cancer?](https://onco.cc/trials/nct02945566/), [Capecitabine/Oxaliplatin Chemotherapy and Cemiplimab With or Without Fianlimab or REGN7075 in Locally Advanced Rectal Cancer](https://onco.cc/trials/nct07281768/), [CapeOX Combined With Bevacizumab Plus Anti-PD1 Antibody as Neoadjuvant Therapy for Locally Recurrent Colorectal Cancer](https://onco.cc/trials/nct06881537/), [CAPEOX vs Observation in Colorectal Cancer Patients With Positive MRD](https://onco.cc/trials/nct05699746/), [CAPOX and Bevacizumab With or Without Primary Tumor Radiotherapy and Iparomlimab and Tuvonralimab as First-line Treatment for RAS-Mutant/MSS Metastatic Rectal C](https://onco.cc/trials/nct07383285/), [CAPOX and PD-1 Antibody Combined With or Without Radiotherapy for MSS Locally Advanced Rectal Cancer](https://onco.cc/trials/nct06281405/), [Cemiplimab With Fianlimab for Resectable Non-Metastatic Colon Cancer](https://onco.cc/trials/nct07224022/), [Cemiplimab With or Without Fianlimab to Treat Older Patients With Localized or Locally Advanced MSI-H Colorectal Cancer](https://onco.cc/trials/nct06205836/), [Cetuximab and Envafolimab Plus mFOLFOXIRI as First-line Treatment for RAS/BRAF Wild-type, MSS, Unresectable Left-side Metastatic Colorectal Cancer](https://onco.cc/trials/nct05959356/), [Cetuximab Plus Irinotecan in Patients With NeoRAS Wild-type Metastatic Colorectal Cancer In Third-line Therapy](https://onco.cc/trials/nct05962502/), [Cetuximab, Irinotecan, Toripalimab in RAS/BRAF Wild-type Ultraselected Right-sided Colorectal Cancer Study](https://onco.cc/trials/nct06547203/), [CGA Guided Ultrafractionated RT and First-line Systemic Treatment in Elderly or Frail Patients with MCRC](https://onco.cc/trials/nct06665087/), [CGA Guided Ultrafractionated RT and Systemic Treatment in Elderly or Frail Patients with Inoperable Localized CRC](https://onco.cc/trials/nct06652412/), [Chidamide in Combination With PD-1 Inhibitor, Bevacizumab, and XELOX for Metastatic Colorectal Cancer](https://onco.cc/trials/nct06858969/), [CIRCULATING TUMOR DNA BASED DECISION FOR ADJUVANT TREATMENT IN COLON CANCER STAGE II](https://onco.cc/trials/nct04120701/), [Circulating Tumor DNA Methylation Guided Postoperative Adjuvant Chemotherapy for High-risk Stage II/III Colorectal Cancer](https://onco.cc/trials/nct05954078/), [Circulating Tumor DNA Testing in Predicting Treatment for Patients With Stage IIA Colon Cancer After Surgery](https://onco.cc/trials/nct04068103/), [Circulating Tumor DNA-guided Neoadjuvant Treatment Strategy for Locally Advanced Rectal Cancer](https://onco.cc/trials/nct05601505/), [Clinical Efficacy of Transarterial Chemoembolization in Elderly Patients With Advanced Unresectable Colorectal Cancer](https://onco.cc/trials/nct07209384/), [Clinical Study of Irinotecan Liposome (II)-Based Combination Treatment for Irinotecan-resistant Colorectal Cancer.](https://onco.cc/trials/nct07044921/), [Clinical Study of Second-line Treatment in Advanced Colorectal Cancer With Chemotherapy With Bevacizumab or Cetuximab](https://onco.cc/trials/nct06540326/), [Clinical Study of Short-course Radiotherapy Followed by Fruquintinib Plus Sintilimab vs Bevacizumab Plus Capecitabine as First Line Treatment in Advanced mCRC](https://onco.cc/trials/nct06195670/), [Clinical Study on the First-line Treatment of Advanced Colorectal Cancer With Simultaneous Infusion of Levozolinate for Injection and 5-FU](https://onco.cc/trials/nct07391618/), [Clinical Trial Evaluating the Activity of Zanidatamab for the Treatment of Patients With Solid Tumors With an Alteration of the HER2 Gene.](https://onco.cc/trials/nct07192068/), [Clinical Trial Evaluating the Efficacy of Capecitabine Plus Lenvatinib in Patients With Advanced Colorectal Cancer Refractory to Irinotecan, Oxaliplatin, and Fl](https://onco.cc/trials/nct07683949/), [Clinical Trial of Neoadjuvant mFOLFOX Plus Alvenor for LARC Patients With High YWHAB Expression](https://onco.cc/trials/nct07176182/), [Clinical Trial of TB511 in Advanced Solid Tumors](https://onco.cc/trials/nct06400160/), [COffee and Metabolites Modulating the Gut MicrobiomE in Colorectal caNCER](https://onco.cc/trials/nct05692024/), [COLDFIRE-III Trial: Efficacy of Irreversible Electroporation and Stereotactic Body Radiotherapy for Perivascular and Peribiliary Colorectal Liver Metastases](https://onco.cc/trials/nct06185556/), [COLLISION RELAPSE Trial](https://onco.cc/trials/nct05861505/), [Colon Cancer Diagnosis With FAPI-PET Imaging](https://onco.cc/trials/nct07272772/), [Colorectal Metastasis Prevention International Trial 2](https://onco.cc/trials/nct03919461/), [Combination Immunotherapy for the Treatment of Chemotherapy-refractory Metastatic MSS CRC](https://onco.cc/trials/nct07281716/), [Combination of High and Low-Dose Radiotherapy With Immune Therapy and TKI in Advanced Colorectal Cancer: A Phase II Study](https://onco.cc/trials/nct07467590/), [Combination of IV Ascorbic Acid and Adebrelimab in Metastatic Colorectal Cancer](https://onco.cc/trials/nct04516681/), [Combination Therapy for BRAF-V600E Metastatic CRCm](https://onco.cc/trials/nct06411600/), [Combination With Sintilimab and XELOX+Bevacizumab as 1st Line Therapy in RAS-mutant Metastatic Colorectal Cancer](https://onco.cc/trials/nct05171660/), [Combining DCSZ11 With Radiation and Chemotherapy as Neoadjuvant Treatment for pMMR Locally Advanced Rectal Cancer](https://onco.cc/trials/nct07580339/), [Combining Intratumoral Flu Vaccine and Systemic Pembrolizumab in Patients With Early pMMR Colorectal Cancer](https://onco.cc/trials/nct05909423/), [Comparative Study on the Short- and Long-term Efficacy of Q-ISR, Traditional Sub-ISR, and t-ISR](https://onco.cc/trials/nct07371273/), [Comparing Chidamide+Sintilimab+Bev With Standard Second-line FOLFIRI+Bev in Advanced MSS/pMMR mCRC](https://onco.cc/trials/nct05768503/), [Comparing Efficacy and Safety of Enlituo® Versus Erbitux® Plus FOLFOX in Locally Advanced/Metastatic Colorectal Cancer With RAS/BRAF Wild-type and MSS/pMMR Stat](https://onco.cc/trials/nct07595276/), [CompariSon Between the EuroPeAn and Japanese pathologiCal InvEstigation for Colon Cancer (SPACE)](https://onco.cc/trials/nct06119867/), [Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW)](https://onco.cc/trials/nct06265285/), [Comparison of the Pathological Effect Between 2 and 4 Cycles Neoadjuvant CAPOX for Low/Intermediate Risk II/III Rectal Cancer](https://onco.cc/trials/nct04922853/), [Comparison of Transanal Irrigation and Glycerol Suppositories in Treatment of Low Anterior Resection Syndrome](https://onco.cc/trials/nct04087421/), [Consolidation Chemotherapy for Locally Advanced Mid or Low Rectal Cancer After Neoadjuvant Concurrent Chemoradiotherapy](https://onco.cc/trials/nct02843191/), [Continuation of Cetuximab Beyond First-Line Progression in Metastatic Colorectal Cancer](https://onco.cc/trials/nct07389265/), [Continuous or Intermittent Cetuximab Plus FOLFIRI as First-line Treatment in RAS/BRAF Wild-type mCRC Patients](https://onco.cc/trials/nct07004413/), [Conversion From Unresectable To Resectable Metastatic Colorectal Cancer.](https://onco.cc/trials/nct03401294/), [Conversion Therapy of RAS/BRAF Wild-Type Colorectal Cancer Patients With Initially Unresectable Liver Metastases](https://onco.cc/trials/nct04687631/), [Cryoablation Combined with Sintilimab Plus Regorafenib in Previously Treated Colorectal Cancer Liver Metastasis](https://onco.cc/trials/nct05057052/), [CtDNA in Adjuvant Chemotherapy of Stage III Colon Cancer (REVISE Trial)](https://onco.cc/trials/nct06242418/), [ctDNA-Based Adjuvant Chemotherapy for High-Risk Rectal Cancer](https://onco.cc/trials/nct07188025/), [ctDNA-guided Adjuvant Chemotherapy in Liver Metastasis of Colorectal Cancer](https://onco.cc/trials/nct05815082/), [ctDNA-Guided Cetuximab or Bevacizumab Plus Trifluridine/Tipiracil in RAS/BRAF Wild-Type mCRC](https://onco.cc/trials/nct07012954/), [ctDNA-guided Selection of Adjuvant Chemotherapy Regimens for Elderly Colon Cancer Patients After Surgery: A Single-center, Randomized, Controlled Study](https://onco.cc/trials/nct06609551/), [ctDNA-Informed Management of Early-Stage Rectal Cancer](https://onco.cc/trials/nct07209215/), [De-scalation or swItch of Treatment According to Circulating tuMOr DNA Variation After 2 Cycles of Doublet Chemotherapy Plus Targeted Agent in Metastatic Unrese](https://onco.cc/trials/nct06446557/), [DEBIRI Plus Chemotherapy vs. Chemotherapy Alone in Colorectal Cancer Liver Metastases](https://onco.cc/trials/nct06555003/), [Delayed Systemic Therapy Following Destructive Local Treatment of Pulmonary Oligometastases After No Evidence of Disease (NED) in Colorectal Cancer.](https://onco.cc/trials/nct06778382/), [DETERMINE Trial Treatment Arm 02: Atezolizumab in Adult, Paediatric and Teenage/Young Adult Patients With Cancers With High Tumour Mutational Burden (TMB) or Mi](https://onco.cc/trials/nct05770102/), [DETERMINE Trial Treatment Arm 05: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Positive Cancers.](https://onco.cc/trials/nct05768178/), [Dietary Arginine Deprivation Combined With Chemoradiotherapy for Neoadjuvant Treatment of Rectal Cancer: A Randomized Controlled Trial](https://onco.cc/trials/nct07755124/), [Different Cycles of Preoperative Neoadjuvant Sintilimab in Mismatch-repair Deficient/microsatellite Instability-high, Locally Advanced Colorectal Cancer](https://onco.cc/trials/nct06698757/), [Different-Dose SCRT Plus CAPOX, PD-1 Blockade and IL-2 in LARC](https://onco.cc/trials/nct07646639/), [DOSAGE Study: Upfront Dose-Reduced Chemotherapy in Older Patients with Metastatic Colorectal Cancer](https://onco.cc/trials/nct06275958/), [Dose Finding, Efficacy and Immunological Response of IP-001 Following MWA or IRE for CRLM](https://onco.cc/trials/nct06630624/), [Dose Individualization of Chemotherapy in Patients With Gastrointestinal Cancers Lacking a Specific Liver Enzyme](https://onco.cc/trials/nct06475352/), [Dual Administration Of Intraperitoneal And Intravenous TROP2-Directed CAR-NK With TGF-Beta Receptor 2 (TGFBR2) Knock Out (KO) Therapy For Colorectal Cancer-Rela](https://onco.cc/trials/nct07411599/), [Dual EGFR/HER2 Blockade Combined With Irinotecan for the Treatment of HER2-Positive Metastatic Colorectal Cancer](https://onco.cc/trials/nct07059338/), [Duloxetine to Prevent Oxaliplatin-Induced Peripheral Neuropathy in Patients With Stage II-III Colorectal Cancer](https://onco.cc/trials/nct04137107/), [Early Commencement of Adjuvant Chemotherapy for Colon Cancer](https://onco.cc/trials/nct01460589/), [Effect of Chemoprevention by Low-dose Aspirin of New or Recurrent Colorectal Adenomas in Patients With Lynch Syndrome](https://onco.cc/trials/nct02813824/), [Effect of Perioperative Intravenous Infusion of Lidocaine on the Postoperative Course and the Immune Response in Patients Undergoing Surgery for Colon Cancer -](https://onco.cc/trials/nct06923787/), [Effect of Perioperative Lidocaine or High-Dose Dexamethasone on Immune Response in Colon Cancer Surgery (PILDI Study)](https://onco.cc/trials/nct07432399/), [EFFECTIVENESS OF EARLY INFORMATION AND ENDORSMENT BY GP TO INCREASE COLONOSCOPY FOLLOW-UP AND REDUCE DELAYS IN PEOPLE WITH A POSITIVE COLORECTAL CANCER SCREENIN](https://onco.cc/trials/nct07520578/), [Effects of Intravenous Administered Iron in Non-anemic Iron Deficient Patients With Colorectal Cancer](https://onco.cc/trials/nct05220800/), [Efficacy and Safety Comparison of Short-course Radiotherapy Followed by CapeOX Chemotherapy Plus Toripalimab With or Without Concurrent Surufatinib in Neoadjuva](https://onco.cc/trials/nct07505472/), [Efficacy and Safety of AK104 Combined With Chemotherapy and Cetuximab or Bevacizumab](https://onco.cc/trials/nct07253896/), [Efficacy and Safety of Chemotherapy With XELOX (Oxaliplatin + Capecitabine) and Bevacizumab in Combination With Adebrelimab in First-line Treatment of Microsate](https://onco.cc/trials/nct06282445/), [Efficacy and Safety of Combined With Immunotherapy After Induction Therapy With Chemotherapy and Targeted Therapy in the First-line Treatment of Microsatellite](https://onco.cc/trials/nct06176885/), [Efficacy and Safety of FOLFOX+Cetuximab vs. FOLFOXIRI+Bevacizumab Both With QL1706 in First-Line Treatment of Left-Sided mCRC](https://onco.cc/trials/nct07070713/), [Efficacy And Safety Of Hydroxychloroquine Combined With Methotrexate, Capecitabine And Bevacizumab Vs. Regorafenib In Participants With Refractory Metastatic Co](https://onco.cc/trials/nct06949982/), [Efficacy and Safety of Retlirafusp Alfa Plus Bevacizumab and Chemotherapy With or Without Short-Course Radiotherapy in Patients With CRCLM](https://onco.cc/trials/nct07728019/), [Efficacy and Safety of Trastuzumab Biosimilars and Pertuzumab Biosimilars Combined With Chemotherapy for Neoadjuvant Treatment of Patients With Locally Advanced](https://onco.cc/trials/nct07108127/), [Efficacy and Safety of Tunlametinib Combination Therapy in the Treatment of Second-line and Above Metastatic Colorectal Cancer](https://onco.cc/trials/nct07714447/), [Efficacy and Toxicity of Total Neoadjuvant Sandwich Treatment Via Short Course Radiotherapy in the Treatment of Stage II and III Rectal Cancer Patients](https://onco.cc/trials/nct07095439/), [Efficacy of Hyperthermic Intraperitoneal Chemotherapy](https://onco.cc/trials/nct04861558/), [Efficacy of the Use of Neoadjuvant With/Without Hyperthermic Intraperitoneal Chemotherapy in the Treatment of Locally Advanced Colon Cancer](https://onco.cc/trials/nct06783491/), [Efficacy Study of Digoxin Combined With Serplulimab and Chemotherapy in First-Line Treatment of MSS Advanced Colorectal Cancer](https://onco.cc/trials/nct07025850/), [Efficacy, Safety and Exploratory Clinical Study of Bevacizumab Combined With Oxaliplatin and TAS-102 in First-line Treatment of Advanced Colorectal Cancer](https://onco.cc/trials/nct05364489/), [Encorafenib + Cetuximab Beyond Progression in Combination With FOLFIRI in Patients With BRAF V600E Mutated Metastatic Colorectal Cancer Progressing on Encorafen](https://onco.cc/trials/nct06640166/), [Encorafenib Plus Cetuximab in a Neoadjuvant Setting in Patients With BRAF Mutation Localised Colon or Upper Rectum Cancer](https://onco.cc/trials/nct05706779/), [Endoscopic Therapy Or Surgery for Early Colon Cancer](https://onco.cc/trials/nct06940947/), [EPA for Metastasis Trial 2](https://onco.cc/trials/nct03428477/), [Epacadostat (INCB024360) Added to Preoperative Chemoradiation in Patients With Locally Advanced Rectal Cancer](https://onco.cc/trials/nct03516708/), [Evaluating the Benefits of Personalized Traditional Chinese Medicine in Postoperative Treatment for Locally Advanced Colorectal Cancer](https://onco.cc/trials/nct06596343/), [Evaluating the Impact of GLP-1 Receptor Agonists With Total Neoadjuvant Therapy in Rectal Cancer](https://onco.cc/trials/nct07314528/), [Evaluating Whether an Educational Website Called Current Together After Cancer (CTAC) Improves Follow-up Care for Colorectal Cancer Survivors](https://onco.cc/trials/nct07018869/), [Evaluation of 89Zr-DFO-nimotuzumab for Non-invasive Imaging of EGFR+ Cancers by Positron Emission Tomography (PET)](https://onco.cc/trials/nct04235114/), [Evaluation of Irinotecan Liposome (II) Combined With 5-FU, LV, and Bevacizumab for mCRC](https://onco.cc/trials/nct06643793/), [Evaluation of Metastatic Disease and Oncological Treatment in Patients With Colon Cancer Using Zebra Fish Avatars](https://onco.cc/trials/nct06270017/), [Evaluation of the Effect of Adapted Physical Activity on the Modification of Lipid Metabolism During Chemotherapy for Metastatic COLorectal Cancer](https://onco.cc/trials/nct06944548/), [Everolimus Combined With PD-1 in Advanced Colorectal Cancer Patients](https://onco.cc/trials/nct06301386/), [Everolimus in CDK12-Deficient Metastatic Colorectal Cancer (EVER-RECODE)](https://onco.cc/trials/nct07435584/), [Exploration of Therapeutic Strategies for NeoRAS Wild-type Metastatic Colorectal Cancer Based on Circulating Tumor DNA](https://onco.cc/trials/nct06440902/), [Exploring Sintilimab + Bevacizumab + Decitabine for Advanced pMMR/MSS Colorectal Cancer (After 2+ Prior Therapies）](https://onco.cc/trials/nct07007767/), [FAPI-Guided Radiotherapy With Cadonilimab and Standard Chemotherapy for Colorectal Peritoneal Metastasis: A Phase III Randomized Controlled Trial (TORHC-PM02)](https://onco.cc/trials/nct07815834/), [Finding the Best Dose of Aspirin to Prevent Lynch Syndrome Cancers](https://onco.cc/trials/nct02497820/), [First-line Treatment of MCapOX + Cetuximab Vs. MFOLFOX6 + Cetuximab for RAS/BRAF Wild-type, MSS, Unresectable Left-Sided MCRC: a Multicenter, Randomized, Contro](https://onco.cc/trials/nct06616259/), [Fluorescence Image Guided Surgery Followed by Intraoperative Photodynamic Therapy for Improving Local Tumor Control in Patients With Locally Advanced or Recurre](https://onco.cc/trials/nct06307548/), [Fluorescence Lymph Node Mapping for Colon Cancer Surgery](https://onco.cc/trials/nct07060443/), [Fluorouracil Treatment Via Colon for Colorectal Cancer](https://onco.cc/trials/nct06385418/), [FMT Combined With Standard First-Line Therapy in Initially Unresectable Colorectal Cancer](https://onco.cc/trials/nct07509398/), [FMT+ QL1706+Bevacizumab+ XELOX as First-line Treatment for Advanced MSS-type Colorectal Cancer With Liver Metastasis](https://onco.cc/trials/nct06801665/), [FOLFIRI Plus Bevacizuamb and QL1706 in Second-Line Treatment for mCRC](https://onco.cc/trials/nct07729605/), [FOLFOX or CAPOX Perioperative Chemotherapy Versus Postoperative Chemotherapy for Locally Advanced Colon Cancer (OPTICAL)](https://onco.cc/trials/nct02572141/), [FOLFOX Via HAI Plus Intravenous Irinotecan With or Without Bevacizumab Versus Systemic FOLFOXIRI With or Without Bevacizumab in Initially Unresectable RAS-mutat](https://onco.cc/trials/nct05727163/), [FOLFOX, Botensilimab, and Balstilimab for the Treatment of Localized Rectal Cancer Before Surgery](https://onco.cc/trials/nct06780787/), [FOLFOX8 Versus mFOLFOX6 With Bevacizumab or Cetuximab for First-Line Unresectable Metastatic Colorectal Cancer (Phase II)](https://onco.cc/trials/nct07621497/), [FOLFOXIRI Plus Bevacizumab With or Without Atezolizumab as 1st Line Treatment of pMMR and IS IC-High Metastatic Colorectal Cancer Patients.](https://onco.cc/trials/nct06733038/), [FOLICOLOR TRIAL: Following Therapy Response Through Liquid Biopsy in Metatstatic Colorectal Cancer Patients](https://onco.cc/trials/nct07558083/), [Fruquintinib and Pirfenidone in Combination With Anti-PD-1 Antibody in Advanced or Metastatic pMMR/MSS Colorectal Carcinoma](https://onco.cc/trials/nct06484153/), [Fruquintinib Combined With Sintilimab ± Radiotherapy for Third-line Treatment of Colorectal Cancer With Liver Metastases](https://onco.cc/trials/nct06356584/), [Fruquintinib Combined With Trifluridine/Tipiracil Versus Bevacizumab Combined With Trifluridine/Tipiracil for Advanced Metastatic Colorectal Cancer](https://onco.cc/trials/nct07286695/), [Fruquintinib In Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies in South Korea Patients (FIRST-K)](https://onco.cc/trials/nct07510932/), [Fruquintinib Plus Anti-EGFR Antibody for Third-Line Treatment of RAS Wild-Type mCRC](https://onco.cc/trials/nct07724223/), [Fruquintinib Plus Camrelizumab and HAIC in the Treatment of Non-MSI-H Advanced Colorectal Cancer](https://onco.cc/trials/nct06423937/), [Fruquintinib Versus Bevacizumab Plus Chemotherapy in Second-Line RAS-Mutant Metastatic Colorectal Cancer (FRU-RAS)](https://onco.cc/trials/nct07362836/), [Fruquintinib vs Bevacizumab Combined With Irinotecan Liposome and Capecitabine as Second-Line Therapy for Advanced Metastatic Colorectal Cancer](https://onco.cc/trials/nct07051785/), [Fruquintinib With or Without HAI-FOLFOX for Refractory Colorectal Cancer](https://onco.cc/trials/nct06441565/), [FTD-TPI, Bevacizumab, and Radioembolization With 166Ho-microspheres in Refractory Metastatic Colorectal Cancer](https://onco.cc/trials/nct06563986/), [FULIRI Plus Targeted Therapy for First-line Conversion Therapy of Colorectal Cancer Liver Metastases.](https://onco.cc/trials/nct07515963/), [Futibatinib in Combination With (Chemo)Immunotherapy in Colorectal Cancer and Other Solid Tumor Entities](https://onco.cc/trials/nct06722183/), [Glumetinib Combined With Fruquintinib in the Treatment of MET Amplification or Protein Overexpression in Third-Line Unresectable Metastatic Colorectal Cancer](https://onco.cc/trials/nct06980532/), [Gossypol Acetate + FOLFIRI + Bev in mCRC With TP53-Mutant and LRPPRC Positive](https://onco.cc/trials/nct07337551/), [GSL Synthetase Inhibitor Plus Immune Checkpoint Inhibitor and/or Regorafenib in Previously Treated pMMR/MSS CRC.](https://onco.cc/trials/nct06558773/), [HDAC Inhibitor Combination With Chemoimmunotherapy in the Neoadjuvant Treatment of pMMR Locally Advanced Colon Cancer](https://onco.cc/trials/nct06709885/), [Hepatic Arterial Infusion Chemotherapy in Patients With Inoperable Colorectal Cancer Liver Metastasis](https://onco.cc/trials/nct07764497/), [Hepatic Arterial Infusion of Liposomal Irinotecan Plus Oxaliplatin and Capecitabine as Adjuvant Therapy for Colorectal Cancer Liver Metastases](https://onco.cc/trials/nct07570914/), [HRX215, A First Generation MKK4 Inhibitor Drug, for the Treatment of Patients With Colorectal Liver Metastasis After Undergoing a Portal Vein Embolization](https://onco.cc/trials/nct07612007/), [Hyperthermia Enhanced Re-irradiation of Loco-regional Recurrent Tumors](https://onco.cc/trials/nct04889742/), [Hypofractionated Radiotherapy Combined With NALIRIF, PD-1 Antibody in Locally Recurrent Rectal Cancer(NOVELTY-R)](https://onco.cc/trials/nct07183865/), [Hypofractionated Radiotherapy Plus Immunotherapy Versus Conventional Radiotherapy in Locally Recurrent Rectal Cancer](https://onco.cc/trials/nct06928584/), [ICE Study: Combination of Irinotecan Plus Cetuximab and Envafolimab as a Rechallenge Regimen in mCRC](https://onco.cc/trials/nct06321081/), [Identification and Treatment Of Micrometastatic Disease in Stage III Colon Cancer](https://onco.cc/trials/nct03803553/), [Immune Cell Therapy for Advanced Solid Tumors](https://onco.cc/trials/nct07260058/), [Immune Checkpoint Inhibitors + Chemotherapy Versus Chemotherapy in the Neoadjuvant Treatment of Locally Advanced Colorectal Cancer](https://onco.cc/trials/nct06154538/), [Immune Checkpoint Inhibitors for Organ Preservation in Non-metastatic dMMR/MSI-H Gastric or Colon Cancers](https://onco.cc/trials/nct06580574/), [Immunotherapy (Toripalimab) for Reducing Recurrence Risk After Surgery for Mismatch Repair Deficient Stage IIB, IIC, or III Colon Cancer](https://onco.cc/trials/nct07140679/), [Immunotherapy in Patients With Early dMMR Rectal Cancer](https://onco.cc/trials/nct05732389/), [Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer](https://onco.cc/trials/nct01174121/), [Immunotheray Combined With Simvastatin and Target Therapy and Chemotharepy for Advanced Colorectal Cancer](https://onco.cc/trials/nct07718490/), [Improvement Effect of Dexamethasone Enema for Acute Radiation-induced Rectal Injury](https://onco.cc/trials/nct07548736/), [Improving Functional Outcomes and Quality of Life in Patients With Rectal Cancer After Surgery With Intensified Follow-up & Surveillance](https://onco.cc/trials/nct06936774/), [Induction Chemotherapy Combined With Neoadjuvant Immunotherapy for MSS Colon Cancer](https://onco.cc/trials/nct05914389/), [Induction Chemotherapy for Locally Recurrent Rectal Cancer](https://onco.cc/trials/nct04389086/), [Induction Treatment for Initially Unresectable Colorectal Liver Metastases: Combined Hepatic Arterial Infusion Pump Therapy With Systemic Therapy](https://onco.cc/trials/nct06857773/), [Injection of IP-001 Into Thermally Ablated Hepatic Tumors in Patients With Colorectal Liver Metastases](https://onco.cc/trials/nct07321847/), [Interest of Early Erectile Rehabilitation With Sildenafil After Radiotherapy and Proctectomy for Rectal Cancer](https://onco.cc/trials/nct06123156/), [Intermittent or Continuous Panitumumab Plus FOLFIRI for Left Sided RAS/B-RAF Wild-type Metastatic Colorectal Cancer](https://onco.cc/trials/nct06509126/), [Intestinal Microbiome Modulation With Antibiotics in the Neoadjuvant Treatment of Locally Advanced Rectal Cancer](https://onco.cc/trials/nct06793137/), [Intraoperative Indocyanine Green Fluorescence Angiography in Colorectal Surgery to Prevent Anastomotic Leakage](https://onco.cc/trials/nct05168839/), [Investigate the Efficacy of Chemotherapy in Patients With Positive ctDNA After Surgery and Adjuvant Chemotherapy for a Stage III Colorectal Cancer](https://onco.cc/trials/nct06197425/), [INVESTIGATION OF THE ANTI-NEOPLASTIC EFFECT OF TRISHUL (AYURVEDIC AGENT) ON TUMOUR REGRESSION OF RECTAL CANCER- A PILOT STUDY](https://onco.cc/trials/nct07430696/), [Involve-site Radiotherapy Combined With Chemotherapy and Immunotherapy as Neoadjuvant Treatment for Locally Advanced Rectal Cancer](https://onco.cc/trials/nct07161115/), [Iparomlimab/Tuvonralimab Combined With Bevacizumab and CAPEOX as Conversion Therapy for Colorectal Cancer Liver Metastasis](https://onco.cc/trials/nct07007728/), [Iparomlimab/Tuvonralimab Integrating With Total Neoadjuvant Therapy for pMMR/MSS Locally Advanced Rectal Cancer (IT-TNT)](https://onco.cc/trials/nct07026422/), [Irinotecan Hydrochloride Liposome Injection (II) Combined with Fluorouracil, Folinic Acid, Vermofenib and Cetuximab in First-line Treatment of BRAFV600E Mutated](https://onco.cc/trials/nct06603376/), [Irinotecan Liposomes Combined with Cetuximab + Vermofenib in First-line Failure of Advanced Colorectal Cancer](https://onco.cc/trials/nct06763029/), [Irinotecan Liposomes in Total Neoadjuvant Therapy in Locally Advanced Rectal Cancer](https://onco.cc/trials/nct07074353/), [Irinotecan, TAS-102 Plus Bevacizumab as a Second-Line Therapy in mCRC Patients](https://onco.cc/trials/nct06202001/), [Irreversible Electroporation (NanoKnife ®) and Immunotherapy for the Treatment of Stage IV Colorectal Cancer](https://onco.cc/trials/nct06047015/), [Ivonescimab Plus Chemotherapy in Patients With Initially Unresectable Colorectal Cancer Liver Metastases](https://onco.cc/trials/nct06848842/), [Ivosidenib Plus mFOLFOXIRI and Celecoxib for BRAF-targeted Therapy-refractory BRAF V600E-mutant Colorectal Cancer Patients](https://onco.cc/trials/nct07809893/), [JS212 Combination Therapies in Metastatic Colorectal Cancer](https://onco.cc/trials/nct07503756/), [JSKN003 Versus Physician Choiced Treatment in Patients With HER2-positive and Advanced Colorectal Cancer Who Had Failed to Respond to Oxaliplatin, 5-Fu, and Iri](https://onco.cc/trials/nct07384377/), [KN 046 Plus Regorafenib in MSS Metastatic Colorectal Cancer](https://onco.cc/trials/nct05985109/), [KORTUC (KRC-01) Plus Radiotherapy for Organ Preservation in Rectal Cancer](https://onco.cc/trials/nct07622017/), [Liposomal Irinotecan (II) Fractionated Dosing Combined With 5-FU/LV (FOLFIRInali-3) and Bevacizumab in Second-line Treatment of Advanced Colorectal Cancer: A Si](https://onco.cc/trials/nct07047560/), [Liposomal Irinotecan and Capecitabine Plus Bevacizumab as Second-line Therapy in Metastatic Colorectal Cancer](https://onco.cc/trials/nct06192680/), [Liposomal Irinotecan and Leucovorin/5-fluorouracil Plus Bevacizumab in Metastatic Colorectal Cancer](https://onco.cc/trials/nct06184698/), [Liposomal Irinotecan With TAS102 and Bevacizumab for Patients With Metastatic Colorectal Cancer](https://onco.cc/trials/nct05854498/), [Liposomal Irinotecan, Capecitabine and Enlonstobart With Short-Course Radiotherapy for Locally Advanced Rectal Cancer](https://onco.cc/trials/nct07281157/), [Liver-directed Chemotherapy After Surgery of Liver Metastases of Colorectal Cancer in Patients With High Risk of Recurrence of Their Disease](https://onco.cc/trials/nct07284394/), [Local Methylene Blue Injection for Prevention of Anastomotic Leakage and Permanent Stoma After Low Anterior Resection for Rectal Cancer](https://onco.cc/trials/nct07833319/), [Localized Treatment Versus Palliative Chemotherapy in CRC Patients With 10 or More CRLM](https://onco.cc/trials/nct06208371/), [Long-course Chemoradiotherapy or Short-course Radiotherapy Combined With CAPOX, PD-1antibody, and COX-2 Inhibitor for MSS Locally Advanced Rectal Cancer (SERRAC](https://onco.cc/trials/nct07150949/), [Long-Term Extension Study for Participants Previously Enrolled in an Exelixis-Sponsored Study](https://onco.cc/trials/nct07620574/), [Low Dose, Reduced Frequency Nivolumab for the Treatment of Unresectable or Metastatic Cancer, AFFORD IO Trial](https://onco.cc/trials/nct07576725/), [Low Rectal Cancer Treated With Total Neoadjuvant Therapy Plus Concurrent Tislelizumab Immunotherapy](https://onco.cc/trials/nct07561060/), [Low-dose Immunotherapy in Metastatic and Locally Advanced Colorectal and Gastric MSI/dMMR Cancers](https://onco.cc/trials/nct07542262/), [Low-Dose Radiotherapy to Sensitize Pucotenlimab Plus CAPEOX for pMMR Locally Advanced Rectal Cancer](https://onco.cc/trials/nct07448142/), [Low-dose Trifluridine/Tipiracil With Bevacizumab in mCRC](https://onco.cc/trials/nct07085169/), [LPM6690176 in Combination With Chemotherapy and Bevacizumab in Metastatic Colorectal Cancer Patients With RAS Mutation](https://onco.cc/trials/nct07391566/), [Lubiprostone Combined With Maintenance Therapy for Prevention of Postoperative Recurrence in Peritoneal Metastatic Colorectal Cancer](https://onco.cc/trials/nct07405736/), [Lvosidenib (AK112) Combined With CapeOX and Radiotherapy in Patients With Unresectable Metastatic MSS-type Colorectal Cancer](https://onco.cc/trials/nct06593548/), [Maintenance Tislelizumab + Capecitabine to Treat Metastatic Colorectal Cancer](https://onco.cc/trials/nct05360277/), [Manipulation of the Gut Microbiome by a Standardized Preoperative Diet to Prevent Colorectal Cancer Recurrence and Metastasis Following Surgery](https://onco.cc/trials/nct06349590/), [Mebendazole as Adjuvant Treatment for Colon Cancer](https://onco.cc/trials/nct03925662/), [Megestrol Acetate in Improving Neoadjuvant Chemotherapy-Related Weight Loss in Locally Advanced CRC](https://onco.cc/trials/nct06998758/), [Mesalamine for Colorectal Cancer Prevention Program in Lynch Syndrome](https://onco.cc/trials/nct04920149/), [Metformin for the Treatment of mCRC Patients Undergoing FOLFIRI Plus Target Therapy](https://onco.cc/trials/nct06826092/), [Metronidazole as Preoperative Therapy in CRC / FusoMetro-001](https://onco.cc/trials/nct05748145/), [mFOLFOX6 + Bevacizumab + PD-1 Monoclonal Antibody Vs. mFOLFOX6 in Locally Advanced pMMR/MSS CRC](https://onco.cc/trials/nct06791512/), [mFOLFOXIRI Plus Bevacizumab for Organ Preservation in Locally Advanced Rectal Cancer](https://onco.cc/trials/nct07817888/), [mFOLFOXIRI Plus PD-1 Inhibitor vs mFOLFOX6 as Neoadjuvant Therapy for Locally Advanced Colon Cancer](https://onco.cc/trials/nct06890624/), [Microbiotic Product to Promote Microbiome Health and Improve Chemotherapy Delivery](https://onco.cc/trials/nct05296681/), [MNK Inhibitor AUM001 in Combination With Either Pembrolizumab or Irinotecan to Treat Metastatic Colorectal Cancer](https://onco.cc/trials/nct05462236/), [Modified Long-Course Radiotherapy Followed by Chemotherapy and PD-1 Inhibitor for MSS/pMMR High-risk Mid/Low LARC (MODIFI-RC-I)](https://onco.cc/trials/nct06923345/), [Modified Sandwich Therapeutic Regimen for Locally Advanced Rectal Cancer](https://onco.cc/trials/nct05228431/), [Modulated Electro-Hyperthermia in Combination With Multimodal Therapy for Locally Advanced Rectal Cancer](https://onco.cc/trials/nct07372300/), [NALIRIFOX Plus Targeted Therapy Versus FOLFOX Plus Targeted Therapy as First-line Treatment for Metastatic Colorectal Cancer](https://onco.cc/trials/nct07309289/), [Nanoliposomal Irinotecan, Oxaliplatin Plus Capecitabine As Conversion Therapy of Locally Advanced Colorectal Cancer](https://onco.cc/trials/nct06405139/), [Neo-adjuvant Pembrolizumab and Radiotherapy in Localised MSS Rectal Cancer](https://onco.cc/trials/nct04109755/), [Neoadjuvant ADG126 and Pembrolizumab in Locally Advanced Colorectal Cancer](https://onco.cc/trials/nct06846268/), [Neoadjuvant Botensilimab and Balstilimab for the Treatment of Advanced Resectable Colorectal Cancer NEST3](https://onco.cc/trials/nct07595874/), [Neoadjuvant CAPOX Plus Ivonescimab Versus CAPOX for Locally Advanced Colon Cancer](https://onco.cc/trials/nct06790212/), [Neoadjuvant CAPOX Plus Tislelizumab vs CAPOX in MSS High-Risk Locally Advanced Colon Cancer](https://onco.cc/trials/nct07132008/), [Neoadjuvant CAPOX With or Without Pucotenlimab Plus Selective Radiotherapy for Locally Advanced Rectal Cancer](https://onco.cc/trials/nct07528209/), [Neoadjuvant Chemoradiotherapy Combined With Immunotherapy and Anti-angiogenesis in Treating Locally Advanced Rectal Cancer](https://onco.cc/trials/nct07134218/), [Neoadjuvant Chemoradiotherapy Combined With Tislelizumab in the Treatment of Locally Advanced Rectal Cancer](https://onco.cc/trials/nct05479240/), [Neoadjuvant Chemoradiotherapy Followed by Chemotherapy With or Without Tislelizumab for Resectable Ultra-low Rectal Cancer: The RELIEVE-02 Study](https://onco.cc/trials/nct07132463/), [Neoadjuvant Chemoradiotherapy Plus Sintilimab for Intermediate/High Immunoscore Locally Advanced Rectal Cancer](https://onco.cc/trials/nct05450029/), [Neoadjuvant Chemoradiotherapy Plus Tislelizumab With or Without Probio-M9 in pMMR/MSS Locally Advanced Rectal Cancer](https://onco.cc/trials/nct07458529/), [Neoadjuvant Chemoradiotherapy Versus Total Neoadjuvant Therapy in the Treatment of T3 Rectal Cancer](https://onco.cc/trials/nct06097416/), [Neoadjuvant Chemotherapy and PD-1 Inhibitor for Locally Advanced Rectal Cancer（CONTROL-01）](https://onco.cc/trials/nct06647680/), [Neoadjuvant Chemotherapy for Obstructive Colon cancER First Treated by cOlostomy](https://onco.cc/trials/nct06107920/), [Neoadjuvant Chemotherapy Plus Sequential Immune Checkpoint Inhibitor (ICI) Therapy in Locally Advanced Colon Cancer](https://onco.cc/trials/nct06368141/), [Neoadjuvant Chemotherapy, Anti-PD-1 Antibody and Sitagliptin for Locally Advanced pMMR CRC](https://onco.cc/trials/nct07365592/), [Neoadjuvant Chemotherapy, Excision And Observation vs Chemoradiotherapy For Rectal Cancer](https://onco.cc/trials/nct06205485/), [Neoadjuvant Dupilumab and Toripalimab in MSS CRC Subjects With Resectable Liver Metastases](https://onco.cc/trials/nct07277322/), [Neoadjuvant FOLFIRINOX and Preoperative Chemoradiotherapy for Locally Advanced Rectal Cancer Patients](https://onco.cc/trials/nct06812728/), [Neoadjuvant FOLFOX Chemotherapy for Patients With Locally Advanced Colon Cancer](https://onco.cc/trials/nct03426904/), [Neoadjuvant FOLFOXIRI and Chemoradiotherapy Versus Neoadjuvant CAPOX/FOLFOX and Chemoradiotherapy Followed by Surgery or a Watch-and-Wait Approach in High Risk](https://onco.cc/trials/nct07472868/), [Neoadjuvant FOLFOXIRI Versus CapeOX Chemotherapy for Local Advanced Rectal Cancer](https://onco.cc/trials/nct05201430/), [Neoadjuvant FOLFOXIRI Versus Immediate Surgery for Stage II and III Colon Cancers](https://onco.cc/trials/nct05194878/), [Neoadjuvant Fruquintinib Plus Tislelizumab Combined With mCapeOX Versus CapeOX for Mid-high pMMR/MSS Locally Advanced Rectal Cancer](https://onco.cc/trials/nct06443671/), [Neoadjuvant Immunotherapy ± Radiotherapy in MSI-H/dMMR Locally Advanced Colorectal Cancer](https://onco.cc/trials/nct07403877/), [Neoadjuvant Immunotherapy and Organ-sparing Treatment in Patients With Stage I-III dMMR Colon Cancer](https://onco.cc/trials/nct07409844/), [Neoadjuvant Iparomlimab/Tuvonralimab Plus CAPEOX Versus Iparomlimab/Tuvonralimab Plus CAPEOX and Propranolol for Locally Advanced pMMR Colon Cancer: A Prospecti](https://onco.cc/trials/nct07549906/), [Neoadjuvant Long-course Chemoradiation Plus PD-1 Blockade for Mid-low Locally Advanced Rectal Cancer](https://onco.cc/trials/nct05245474/), [Neoadjuvant mFOLFOX6 Chemotherapy Combined With Anti-PD-1 Therapy in MSS/pMMR Locally Advanced Rectal Cancer (FIRM02 Study)](https://onco.cc/trials/nct07381400/), [Neoadjuvant mFOLFOXIRI Plus Bevacizumab in Patients With High-Risk Locally Advanced Rectal Cancer](https://onco.cc/trials/nct04215731/), [Neoadjuvant Moderately Hypofractionated Radiotherapy Combined with Chemotherapy and Immunotherapy for High-risk LARC](https://onco.cc/trials/nct06599827/), [Neoadjuvant Moderately Hypofractionated Radiotherapy Combined With Chemotherapy and Immunotherapy for High-risk pMMR/MSS Locally Advanced Rectal Cancer: A Prosp](https://onco.cc/trials/nct07527520/), [Neoadjuvant Pembrolizumab and Porustobart in Resectable pMMR/MSS Colon Cancer](https://onco.cc/trials/nct07808151/), [Neoadjuvant Pembrolizumab With a Watch-and-wait Strategy for dMMR/MSI-H Localized Colon Cancer: PREMICES Study.](https://onco.cc/trials/nct06646445/), [Neoadjuvant Radiotherapy Combined With NALIRIFOX and Adebrelimab in pMMR/MSS Locally Advanced Rectal Cancer: A Prospective, Randomized, Phase II Clinical Trial](https://onco.cc/trials/nct07622771/), [Neoadjuvant Radiotherapy for Rectal Adenocarcinoma With Capecitabine Versus TAS-102 (Neo-REACT): A Multi-center, Randomized, Phase III Trial](https://onco.cc/trials/nct06850090/), [Neoadjuvant Serplulimab & Bevacizumab With FOLFOX vs. FOLFOX Alone in RAS/BRAF WT, pMMR/MSS CRC Patients](https://onco.cc/trials/nct06280495/), [Neoadjuvant Short-course Radiotherapy Followed by a Combination of Disitamab Vedotin, Sintilimab, and Capecitabine in Locally Advanced HER2-expressing Rectal Ca](https://onco.cc/trials/nct07509424/), [Neoadjuvant Short-Course Radiotherapy With or Without Chemotherapy and AK112 in Locally Advanced Rectal Cancer](https://onco.cc/trials/nct06718543/), [Neoadjuvant SHR-1701 Plus Chemoradiotherapy for Locally Advanced Rectal Cancer](https://onco.cc/trials/nct07478731/), [Neoadjuvant Therapy for Locally Advanced Low Rectal Cancer (SMARTi-RC01)](https://onco.cc/trials/nct07134101/), [Neoadjuvant Therapy vs Standard Therapy in Locally Advanced Rectal Cancer](https://onco.cc/trials/nct05378919/), [Neoadjuvant Toripalimab With or Without Celecoxib in dMMR/MSI-H Colorectal Cancer](https://onco.cc/trials/nct03926338/), [Neoadjuvant Treatment With mFOLFOXIRI Plus Cadonilimab (AK104) Versus mFOLFOX6 in Locally Advanced Colorectal Cancer](https://onco.cc/trials/nct05571644/), [Neoantigen Dendritic Cell Vaccine and Nivolumab in HCC and Liver Metastases From CRC](https://onco.cc/trials/nct04912765/), [Neuroprotection of Memantine and Rosuvastatin](https://onco.cc/trials/nct07504198/), [New Second-Line Combo Therapy for MSS Metastatic Colorectal Cancer](https://onco.cc/trials/nct07559760/), [NIMBLE-CRC: NeoImmunoModulation Before Leveraging Excision in Colorectal Rectal Cancer](https://onco.cc/trials/nct07677579/), [Nimotuzumab Combined With Trifluridine/Tipiracil in the Treatment of Refractory Metastatic Colorectal Cancer](https://onco.cc/trials/nct06343116/), [Nivolumab and Ipilimumab in Anti-PD1-Resistant dMMR/MSI mCRC](https://onco.cc/trials/nct05310643/), [Nocardia Rubra Cell Wall Skeleton in Combination With Prior Second- or Third-line Regimens for the Treatment of Potentially Hazardous Colorectal Cancer SD Statu](https://onco.cc/trials/nct06356714/), [Nodal-Region Sparing Short-Course RT With Chemo-PD-1/Bevacizumab vs. Short-Course RT With Chemotherapy as TNT in pMMR/MSS Locally Advanced Rectal Cancer](https://onco.cc/trials/nct07674732/), [Node-Sparing Hypofractionated Radiotherapy Plus Chemotherapy and PD-1 Inhibitor in pMMR/MSS High-Risk Locally Advanced Colon Cancer: A Prospective, Randomized,](https://onco.cc/trials/nct07230639/), [Node-Sparing Low-Dose Radiotherapy Concurrent With Chemotherapy and PD-1 Inhibitor in pMMR/MSS High-Risk Locally Advanced Colon Cancer: A Prospective, Single-Ar](https://onco.cc/trials/nct07279077/), [Node-sparing Radiotherapy Combined With Total Neoadjuvant CAPOX and Sintilimab for MSS Middle and Low Rectal Cancer](https://onco.cc/trials/nct06204094/), [Node-Sparing Short-Course Radiation Combined With Capecitabine and PD-1/CTLA-4 for MSS Early Rectal Cancer](https://onco.cc/trials/nct07068763/), [Node-sparing Short-Course Radiation Combined With CAPOX and Tislelizumab for MSS Rectal Cancer](https://onco.cc/trials/nct06507371/), [Node-Sparing Short-Course Radiation With CAPOX and Sintilimab for MSS Locally Advanced Colon Cancer: A Randomized, Prospective, Multicenter Study](https://onco.cc/trials/nct06594692/), [Node-Sparing Short-Course Radiotherapy Plus Chemotherapy, Bevacizumab and PD-1 Inhibitor in Metastatic pMMR/MSS Colorectal Cancer (MODIFI-CRC)](https://onco.cc/trials/nct06958419/), [Node-Sparing Short-Course Radiotherapy Sequential Chemotherapy and PD-1 Inhibitor for Mid/Low pMMR/MSS Rectal Cancer (MODIFI-RC-II)](https://onco.cc/trials/nct06958432/), [Nodes-sparing Short-course Radiation Combined With CAPOX and Tislelizumab for MSS Middle and Low Rectal Cancer](https://onco.cc/trials/nct05972655/), [Non Inferiority Study of Preoperative Chemotherapy Without Pelvic Irradiation for Rectal Cancer](https://onco.cc/trials/nct03875781/), [Octreotide Acetate and Recombinant Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor](https://onco.cc/trials/nct00569127/), [Oncolytic Virus (H101) + SBRT + Chemotherapy + Targeted Therapy + Immunotherapy for Unresectable CRLM](https://onco.cc/trials/nct07381309/), [Open-label Phase 2 Study of Avutometinib (RAF/MEK Clamp) in Combination With Defactinib (FAK Inhibitor) and Cetuximab in Patients With Unresectable, Anti-EGFR-R](https://onco.cc/trials/nct06369259/), [OPTIMIzation of Treatment SElection and Follow up in Oligometastatic Colorectal Cancer](https://onco.cc/trials/nct04680260/), [Optimizing Immunotherapy Combined With Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer](https://onco.cc/trials/nct07040098/), [Oral Chemotherapy, Targeted Therapy and Immunotherapy With/Without Radiotherapy as 3rd- or Later-line Therapy for Advanced MSS/pMMR Colorectal Cancer](https://onco.cc/trials/nct06764680/), [Organ Preservation Following Enverolimab-based Total Neoadjuvant Therapy for Locally Advanced Very Low Rectal Cancer](https://onco.cc/trials/nct05969847/), [Organ Preservation in Rectal AdenoCa Using Hypofractionated Pelvic RT(Hypo-OPRA)](https://onco.cc/trials/nct06991465/), [Organ Preservation Strategy of Total Neoadjuvant Chemoradiotherapy for Low Rectal Carcinoma](https://onco.cc/trials/nct05563922/), [Organ Preservation With Tislelizumab and Total Neoadjuvant Therapy in Patients With Low Rectal Cancer: RELIEVE -01 Study](https://onco.cc/trials/nct06390982/), [Other Oncogene Mutations for Anti-EGFR Efficacy in Patients With Left-sided RAS-wild Type Metastatic Colorectal Cancer](https://onco.cc/trials/nct06226857/), [PACE: PD-1 Antibody For dMMR/MSI-H Stage III Colorectal Cancer](https://onco.cc/trials/nct05236972/), [Partial Liver Segment 2/3 Transplantation Study](https://onco.cc/trials/nct02215889/), [Patient Preference for Subcutaneous vs. Intravenous Immune Therapy](https://onco.cc/trials/nct07223424/), [PCSK9 Inhibitors in Combination With Advanced Treatment Strategies for the Treatment of Advanced Colorectal Cancer With pMMR/MSS](https://onco.cc/trials/nct06391905/), [PD-1 + FOLFOXIRI vs CAPOX as Total Neoadjuvant Therapy for pMMR Low Rectal Cancer](https://onco.cc/trials/nct07277842/), [PDS01ADC in Combination With Hepatic Artery Infusion Pump (HAIP) and Systemic Therapy for Subjects With Metastatic Colorectal Cancer, Intrahepatic Cholangiocarc](https://onco.cc/trials/nct05286814/), [Pembrolizumab With Ataluren in Patients With Metastatic pMMR and dMMR Colorectal Carcinoma or Metastatic dMMR Endometrial Carcinoma: the ATAPEMBRO Study](https://onco.cc/trials/nct04014530/), [Pencil Beam Proton Therapy for Pelvic Recurrences in Rectal Cancer Patients Previously Treated With Radiotherapy](https://onco.cc/trials/nct04695782/), [Perioperative Systemic Therapy for Isolated Resectable Colorectal Peritoneal Metastases](https://onco.cc/trials/nct02758951/), [Perioperative Versus Postoperative CapOX Chemotherapy for Locally Advanced Colon Cancer](https://onco.cc/trials/nct03125980/), [Personalising and Refining Neo-adjuvant Chemotherapy in Locally Advanced but Resecable Colon Cancer in the Elderly of 70 Years Old or More](https://onco.cc/trials/nct06293625/), [Personalized Long-course Radiotherapy Plus Chemotherapy With or Without Immunotherapy for LARC: PALACE Study](https://onco.cc/trials/nct07020247/), [Personalized Ultrafractionated Stereotactic Adaptive Radiotherapy (PULSAR ) Combined With Anti-PD1，Chemotherapy and Target Therapy for Metastatic Colorectal Can](https://onco.cc/trials/nct06841159/), [Personalizing Chemotherapy Selection After Surgery for Patients With Stage III Colorectal Cancer Using a Blood Test](https://onco.cc/trials/nct07340567/), [PET/MRI in Rectal Cancer](https://onco.cc/trials/nct06057831/), [Ph II Intraperitoneal Paclitaxel + System Therapy in GI Ca w/Peritoneal Carcinomatosis (STOPGAP-B)](https://onco.cc/trials/nct07795749/), [Ph II Study of Enfortumab Vedotin in Patients With Advanced or Metastatic CRC or HCC](https://onco.cc/trials/nct06553885/), [Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies](https://onco.cc/trials/nct05786924/), [Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation](https://onco.cc/trials/nct07292298/), [Phase I/II Study of the Combination Immunotherapy Regimen: SX-682, TriAdeno Vaccine, Retifanlimab and IL-15 Agonist N-803 (STAR15) for Metastatic Colorectal Can](https://onco.cc/trials/nct06149481/), [Phase Ib/II Study of QL1706 + Fruquintinib + SCRT vs. Standard Third-Line Therapy in Unresectable Liver-Metastatic pMMR/MSS Colorectal Cancer: Safety, Tolerabil](https://onco.cc/trials/nct07353268/), [Phase II Basket Trial: Zanidatamab Plus Tislelizumab in HER2-Positive GI Tumors (UNION-HER2-BASKET)](https://onco.cc/trials/nct07243938/), [Phase II Clinical Study to Evaluate the Efficacy and Safety of HLX07+HLX10 +mFOLFOX6 or HLX07 Monotherapy in Patients With mCRC](https://onco.cc/trials/nct05239650/), [Phase II Clinical Trial of Cadonilimab Combined With Anti-angiogenic Agents in Metastatic dMMR/MSI-H CRC](https://onco.cc/trials/nct07003022/), [Phase II Open-label Trial of Neoadjuvant Immunochemotherapy for Resectable Non-metastatic Colon cancER: NICER](https://onco.cc/trials/nct05870800/), [Phase II RCT of LCRT vs SCRT + CAPOX/PD-1i/COX-2i in MSS Locally Advanced Rectal Cancer](https://onco.cc/trials/nct07154316/), [Phase II Study of Anti-PD-1/VEGF Bispecific Antibody Ivonescimab in Patients With Previously Treated Metastatic Colorectal Cancer](https://onco.cc/trials/nct06959550/), [Phase II Study of Irinotecan Liposomes in First-line Treatment of Metastatic Colorectal Cancer](https://onco.cc/trials/nct06341296/), [Phase II Study of Neoadjuvant Dostarlimab in Patients With Untreated T3-4N0-2 or Stage III pMMR/MSS Resectable Colon Cancer](https://onco.cc/trials/nct06830239/), [Phase II Study of Serplulimab Combined with First-Line Targeted Therapy, Chemotherapy, and Radiation in Advanced Colorectal Cancer](https://onco.cc/trials/nct06521866/), [Phase II Trial of Lung Chemoemobolization](https://onco.cc/trials/nct05672108/), [Phase III Study in First-line Treatment of Patients With Metastatic Colorectal Cancer Who Are Not Candidate for Intensive Therapy.](https://onco.cc/trials/nct03869892/), [Planed Organ Preservation for Low Rectal Cancer After Neoadjuvant Chemotherapy (OPLAR)](https://onco.cc/trials/nct07070622/), [Platform Study of Circulating Tumor DNA Directed Adjuvant Chemotherapy in Colon Cancer (KCSG CO22-12)](https://onco.cc/trials/nct05534087/), [Platform Study of Immunotherapy Combinations in Colorectal Cancer Liver Metastases](https://onco.cc/trials/nct06300463/), [Post-resection/Ablation Chemotherapy in Patients With Metastatic Colorectal Cancer (FIRE-9 - PORT / AIO-KRK-0418)](https://onco.cc/trials/nct05008809/), [Postoperation Maintenance Therapy for Resectable Liver Metastases of Colorectal Cancer Guided by ctDNA](https://onco.cc/trials/nct05797077/), [PRE-ISPY Phase I/II Oncology Platform Program](https://onco.cc/trials/nct05868226/), [Pre-operative Targeted Treatments in Molecularly Selected Resectable Colorectal Cancer (UNICORN)](https://onco.cc/trials/nct05845450/), [Pre-Operative Treatment in REseCTable COlon CanceR](https://onco.cc/trials/nct06899477/), [Preoperative Chemoradiotherapy and Toripalimab in Locally Recurrent Rectal Cancer](https://onco.cc/trials/nct06751394/), [Preoperative Chemoradiotherapy and Transanal Endoscopic Microsurgery Versus Ttransanal Endoscopic Microsurgery in T1 N0, M0 Rectal Cancer (TAUTEM-T1 Study)](https://onco.cc/trials/nct06450574/), [Preoperative Chemoradiotherapy With CApecitabine and Temozolomide in MGMT Silenced, MSS, Locally Advanced RecTal Cancer](https://onco.cc/trials/nct05136326/), [Preoperative FOLFOX Versus Postoperative Risk-adapted Chemotherapy in Patients With Locally Advanced Rectal Cancer](https://onco.cc/trials/nct04495088/), [Preoperative Short-course Radiation Followed by Envafolimab Plus CAPEOX for MSS Locally Advanced Rectal Adenocarcinoma](https://onco.cc/trials/nct05752136/), [Pressurized Intraperitoneal Aerosolized Chemotherapy With Mitomycin for the Treatment of Unresectable Appendix or Colorectal Cancer With Peritoneal Metastases,](https://onco.cc/trials/nct07271355/), [Preventive Efficacy of Bergmann Enema for Acute Radiation-induced Rectal Injury in Rectal Cancer Patients Undergoing Short-course Radiotherapy](https://onco.cc/trials/nct07302126/), [PRODIGE 90 - (FFCD 2204) Neoadjuvant Dostarlimab with Short Course Radiotherapy in a Watch-and-wait Strategy for Microsatellite Unstable or Mismatch Repair-defi](https://onco.cc/trials/nct06762405/), [Prophylactic Mesalamine to Prevent Colitis Following Treatment With Ipilimumab/Nivolumab (Ipi/Nivo)](https://onco.cc/trials/nct05663775/), [Prophylactic Mesh Placement During Stoma Closure After Low Anterior Resection](https://onco.cc/trials/nct05939687/), [Prophylactic PIPAC in Patients With High-risk Colorectal Cancer](https://onco.cc/trials/nct06839092/), [Prospectively Randomized Control Clinical Trial of FOLFOXIRI Preoperative Chemotherapy Alone on Rectal Cancer in Local Advance Comparing to Oral Capecitabine Co](https://onco.cc/trials/nct03671252/), [Protective Role of Alpha-Lipoic Acid in Chemotherapy-Induced Mucositis](https://onco.cc/trials/nct07736495/), [Pucotenlimab Plus Radiotherapy and Chemotherapy for Neoadjuvant Treatment of Locally Advanced Rectal Cance(PUCRT)](https://onco.cc/trials/nct06770270/), [Pulmonary Suffusion in Controlling Minimal Residual Disease in Patients With Sarcoma or Colorectal Metastases](https://onco.cc/trials/nct03965234/), [PULSAR Combined With PD-1 Ab and Chemotherapy Plus Bev. for CRLM](https://onco.cc/trials/nct06788171/), [QL1706 Combined With Standard Therapy for Conversion Therapy of Synchronous Liver Metastases From Colon Cancer: a Multicenter, Single-arm, Exploratory Study](https://onco.cc/trials/nct07649473/), [QL1706 Injection Plus Bevacizumab and XELOX vs Placebo Plus Bevacizumab and XELOX as First-Line Treatment of Unresectable Metastatic Colorectal Cancer](https://onco.cc/trials/nct07025239/), [QL1706 Plus Bevacizumab for Unresectable or Metastatic MSI-H/dMMR CRC](https://onco.cc/trials/nct07009145/), [QL1706 Plus XELOX as Neoadjuvant Therapy for MSS/pMMR Clinical Stage III Colon Cancer](https://onco.cc/trials/nct07156682/), [QL1706 With Short-Course Radiotherapy and Chemotherapy for MSS Rectal Cancer](https://onco.cc/trials/nct07175636/), [QoL in mCRC Elderly Patients Receiving First-line Therapy Based on Simplified Geriatric Parameters.](https://onco.cc/trials/nct03828227/), [Radiotherapy + Systemic Therapy as Conversion Therapy for pMMR/MSS T4M0 Colon Cancer（Neo-Color）](https://onco.cc/trials/nct06949111/), [Radiotherapy Combined QL1706, TAS-102 and Bevacizumab in mCRC](https://onco.cc/trials/nct07116577/), [Radiotherapy Combined With Capeox Chemotherapy, Sintilimab and Suvemcitug in Locally Advanced pMMR Rectal Cancer:a Prospective Clinical Trial](https://onco.cc/trials/nct07774754/), [Radiotherapy Plus CAPOX, and Iparomlimab and Tuvonralimab (QL1706) as Neoadjuvant Therapy for LARC](https://onco.cc/trials/nct07291401/), [Radiotherapy Plus Iparomlimab and Tuvonralimab (QL1706), Regorafenib, and CAPOX as Neoadjuvant Therapy for pMMR/MSS LARC.](https://onco.cc/trials/nct06911684/), [Randomized Controlled Study of Plasma ctDNA Methylation-Guided Adjuvant Chemotherapy in Stage I/Low-Risk Stage II Colorectal Cancer](https://onco.cc/trials/nct07562659/), [Randomized Study of Plasma ctDNA Methylation to Guide Adjuvant Chemotherapy Decisions in High-Risk T3N0 Colorectal Cancer](https://onco.cc/trials/nct07562711/), [Randomized Trial of Plasma ctDNA Methylation-Guided Adjuvant Therapy in T4N0 and Low-Risk Stage III Colorectal Cancer](https://onco.cc/trials/nct07562503/), [Randomizing Two Radiotherapy Boost Options to Avoid Rectal Cancer Surgery](https://onco.cc/trials/nct03051464/), [Re-irradiation Therapy of Locally Recurrent Rectal Cancer With Carbon Ion](https://onco.cc/trials/nct05807984/), [RECTIFY-1: Neoadjuvant Botensilimab + Balstilimab in MSS/pMMR Early Rectal Cancer](https://onco.cc/trials/nct07735624/), [Regorafenib (Reg) and Lorigerlimab (Lor), RELO Regimen, in Treatment of High-risk Patients With Colorectal Cancer With Radiographic Occult Molecular Residual Di](https://onco.cc/trials/nct07071961/), [Regorafenib Alone or in Combination With Hypofractionated/Low-dose Radiotherapy Plus Toripalimab for Metastatic Colorectal Cancer](https://onco.cc/trials/nct05963490/), [Regorafenib Combined With Irinotecan Drug-Eluting Beads for Colorectal Cancer Liver Metastases](https://onco.cc/trials/nct05794971/), [Regorafenib in Combination With Multimodal Metronomic Chemotherapy for Chemo-resistant Metastatic Colorectal Cancers](https://onco.cc/trials/nct06425133/), [Regorafenib With Low-dose Chemotherapies and Aspirin Followed by Standard Chemotherapies in Metastatic Colorectal Cancer](https://onco.cc/trials/nct05462613/), [Retlirafusp Alfa Plus Targeted Therapy and Chemotherapy for Unresectable Colorectal Liver-Limited Metastases](https://onco.cc/trials/nct07815288/), [Riluzole For Preventing Cognitive Dysfunction in Ca Pts Receiving Chemo (REFOCUS): Pilot Trial](https://onco.cc/trials/nct07447050/), [Rimegepant Combined With PD-1 in Liver Metastasis Colorectal Cancer Patients](https://onco.cc/trials/nct06999252/), [ROMANCE: "Irinotecan Plus Cetuximab Rechallenge Versus Trifluridine/Tipiracil Plus Bevacizumab in Molecularly Selected Metastatic Colorectal Cancer"](https://onco.cc/trials/nct07381764/), [rSIFN-co in Combination With Total Neo-adjuvant Therapy in Subjects With Mid-low Locally Advanced Rectal Cancer](https://onco.cc/trials/nct07662278/), [S0820, Adenoma and Second Primary Prevention Trial](https://onco.cc/trials/nct01349881/), [Sacituzumab Govitecan in Metastatic Colorectal Cancer](https://onco.cc/trials/nct06243393/), [Safety and Effectiveness Study of Pre-operative Artesunate in Stage II/ III Colorectal Cancer](https://onco.cc/trials/nct07095309/), [Safety and Efficacy of Fruquintinib Plus Chidamide and Sintilimab in the Third and Later Line Treatment of MSS/pMMR Metastatic Colorectal Cancer](https://onco.cc/trials/nct06685276/), [Safety and Efficacy of IB-FOLFIRI in BRAF V600E-Mutant Metastatic Colorectal Cancer](https://onco.cc/trials/nct07150247/), [Safety and Efficacy of PD-1 ± mFOLFOX6 Neoadjuvant Therapy in Local Advanced sMPCC](https://onco.cc/trials/nct06002789/), [Safety and Efficacy of Tegavivint in Patients With Metastatic Colorectal Carcinoma](https://onco.cc/trials/nct07463599/), [Safety of a Boost (CXB or EBRT) in Combination With Neoadjuvant Chemoradiotherapy for Early Rectal Adenocarcinoma](https://onco.cc/trials/nct02505750/), [Safety of HRX215 in Patients After Minor and Major Liver Resection](https://onco.cc/trials/nct06638502/), [Safety of Trifluridine/Tipiracil in Patients With Dihydropyrimidine Dehydrogenase Deficiency Diagnosed With Metastatic Colorectal or Gastroesophageal Cancer](https://onco.cc/trials/nct06245356/), [SAMe in Prevention of Oxaliplatin-associated Liver Injury](https://onco.cc/trials/nct06258525/), [Savolitinib Plus Cetuximab and FOLFOX Chemotherapy for RAS/BRAF Wild-type Metastatic Colorectal Cancer](https://onco.cc/trials/nct07683403/), [SBRT + PD-1 Antibody in Unresectable Locally Recurrent Rectal Cancer（SPARKLE）](https://onco.cc/trials/nct06767007/), [SBRT + PD-1 Monoclonal Antibody in Unresectable Colorectal Liver Metastases](https://onco.cc/trials/nct06794086/), [SBRT Combined With CAPEOX, Bevacizumab, and PD-1 Inhibitor for the Treatment of RAS-Mutant, MSS-Type, Unresectable Metastatic Colorectal Cancer.](https://onco.cc/trials/nct06835179/), [SBRT Combined With Fruquintinib Plus PD-1/CTLA-4 Antibody for Third-line Treatment in mCRC](https://onco.cc/trials/nct05747716/), [SBRT Followed by PD-1 Inhibitor, Bevacizumab and TAS-102 as Third-Line Therapy for Recurrent/Metastatic Colorectal Cancer](https://onco.cc/trials/nct07535632/), [SBRT of Metastases Following Neo-adjuvant Treatment for Colorectal Cancer With Synchronous Liver Metastases](https://onco.cc/trials/nct05775146/), [SCRT + Chemo Targeted Immuno-neoadjuvant Therapy for High-risk pMMR/MSS RC](https://onco.cc/trials/nct07549399/), [SCRT Based iTNT vs. LCRT Based TNT for MSS Locally Advanced Rectal Cancer](https://onco.cc/trials/nct07551479/), [SCRT Combined With CAPOX and PD-1/CTLA4 Antibody for Early-stage Low Rectal Cancer](https://onco.cc/trials/nct07837362/), [SCRT Combined With Chemotherapy and Iparomlimab and Tuvonralimab in MSS or pMMR Patients With Locally Advanced Rectal Cancer](https://onco.cc/trials/nct06864013/), [SCRT Followed by AK112 in pMMR/MSS Mid-low Rectal Cancer](https://onco.cc/trials/nct07162714/), [SCRT Followed by CAPOX + Bev ± PD-1 Inhibitor for TNT in LARC](https://onco.cc/trials/nct07198165/), [SCRT Sequential Penpulimab in Combination With CAPEOX in the Neoadjuvant Treatment of MSS Locally Advanced Rectal Cancer](https://onco.cc/trials/nct05576480/), [SCRT VS LCRT Followed by PD-L1 Inhibitor Plus CAPEOX as TNT in Patients With LARC](https://onco.cc/trials/nct07284992/), [SCRT-CAPEOX-Serplulimab for MSS/pMMR Rectal Cancer With Oligometastases](https://onco.cc/trials/nct06850103/), [SCRT(Short Course Radiotherapy) Combined With CAPOX Plus QL1706 for Rectal Cancer Liver Metastases](https://onco.cc/trials/nct06787183/), [Second and Third Look Laparoscopy in pT4 Colon Cancer Patients for Early Detection of Peritoneal Metastases](https://onco.cc/trials/nct03413254/), [Second-line Doublet Chemotherapy (FOLFOX or FOLFIRI) Plus Fruquintinib Versus Doublet Chemotherapy (FOLFOX or FOLFIRI) Plus Bevacizumab in Metastatic Colorectal](https://onco.cc/trials/nct07150403/), [Second-line Standard Treatment Sequential TAS-102 and Bevacizumab Combined With Local Treatment in Advanced Colorectal Cancer](https://onco.cc/trials/nct06856187/), [Second-line Treatment of Metastatic Colorectal Cancer](https://onco.cc/trials/nct06242067/), [Self-Management Survivorship Care in Stage I-III Non-small Cell Lung Cancer or Colorectal Cancer](https://onco.cc/trials/nct04428905/), [Sequential Immunochemotherapy Treatment with Pembrolizumab Plus Dendritic Cell (DC) Vaccine Followed by Trifluridine/Tipiracil Plus Bevacizumab in Refractory Mi](https://onco.cc/trials/nct06522919/), [Sequential TAS-OX Alternating With TAS-IRI Plus Bevacizumab for Late-Line Metastatic Colorectal Cancer](https://onco.cc/trials/nct05806931/), [Serine/Glycine-Restricted Diet With Chemoradiotherapy for Rectal Cancer](https://onco.cc/trials/nct07811076/), [Serplulimab Combined With CAPEOX + Celecoxib as Neoadjuvant Treatment for Locally Advanced Rectal Cancer](https://onco.cc/trials/nct05731726/), [Serplulimab Combined With CAPOX and Bevacizumab as Neoadjuvant Therapy for Locally Advanced Colorectal Cancer](https://onco.cc/trials/nct07819604/), [Serplulimab Combined With FOLFIRI and Bevacizumab in the Treatment of Colon Cancer Peritoneal Metastases](https://onco.cc/trials/nct05742425/), [Serplulimab Plus Decitabine and CAPOX Before Surgery for Locally Advanced Colorectal Cancer](https://onco.cc/trials/nct07691632/), [Short Course Radiotherapy Followed by CAPOX and Carrilizumab and Bevacizumab or Cetuximab for the Initial Treatment of Unresectable Metastatic Rectal Cancer](https://onco.cc/trials/nct07059949/), [Short RT Versus RCT,Followed by Chemo and Organ Preservation for Interm and High-risk Rectal Cancer Patients](https://onco.cc/trials/nct04246684/), [Short-Course Online Adaptive Radiotherapy Combined With Chemotherapy, Targeted Therapy and Immunotherapy as Total Neoadjuvant Therapy (TNT) for Locally Advanced](https://onco.cc/trials/nct07581626/), [Short-course Radiation (SCRT) Followed by 6 Cycles of Cadonilimab Plus MFOLFOX6 As Neoadjuvant Therapy for Patients with Locally Advanced Rectal Cancer (LARC):](https://onco.cc/trials/nct06832917/), [Short-course Radiotherapy Combined With CapeOx and PD-1 Inhibitor After Local Excision for High-risk Early Rectal Cancer (TORCH-LE)](https://onco.cc/trials/nct06455124/), [Short-course Radiotherapy Combined With CAPOX and PD-1 Antibody Versus Long-course Chemoradiotherapy Combined With CAPOX for Early Low-lying Rectal Cancer](https://onco.cc/trials/nct06462053/), [Short-Course Radiotherapy Combined With Chemotherapy and Immunotherapy in Mid-Low Locally Advanced Rectal Cancer](https://onco.cc/trials/nct07397442/), [Short-course Radiotherapy Combined With Furoquintinib and PD-1 Monoclonal Antibody](https://onco.cc/trials/nct06014944/), [Short-Course Radiotherapy Combined with Intracavitary Brachytherapy Followed by Pucotenlimab, Bevacizumab, Oxaliplatin, and Trifluridine/Tipiracil (TAS-102) for](https://onco.cc/trials/nct06872606/), [Short-course Radiotherapy Followed by AK112 and CAPOX as Neoadjuvant Therapy for Locally Advanced Rectal Cancer](https://onco.cc/trials/nct06802666/), [Short-course Radiotherapy Followed by CAPOX and Ivonescimab for Locally Advanced Rectal Cancer](https://onco.cc/trials/nct06760520/), [Short-Course Radiotherapy Followed by CAPOX With or Without Iparomlimab and Tuvonralimab in pMMR/MSS Locally Advanced Rectal Cancer](https://onco.cc/trials/nct07686640/), [Short-course Radiotherapy Followed by Chemotherapy and PD-1 Inhibitor for Locally Advanced Rectal Cancer](https://onco.cc/trials/nct05484024/), [Short-course Radiotherapy Followed by Fruquintinib Plus Adebrelimab and CAPOX in the Full Course Neoadjuvant Treatment of Locally Advanced Rectal Cancer: a Mult](https://onco.cc/trials/nct06234007/), [Short-Course Radiotherapy Followed by Immunotherapy Combined With Chemotherapy for Microsatellite Stable Locally Advanced Rectal Cancer: A Prospective, Randomiz](https://onco.cc/trials/nct07594925/), [Short-Course Radiotherapy Followed by Neoadjuvant Chemotherapy and Camrelizumab in Locally Advanced Rectal Cancer (UNION)](https://onco.cc/trials/nct04928807/), [Short-Course Radiotherapy Followed by Neoadjuvant Chemotherapy, HLX07and Serplulimab in LARC](https://onco.cc/trials/nct06542588/), [Short-course Radiotherapy Followed by Sequential Chemotherapy With or Without PD-1 Monoclonal Antibody and Bevacizumab as Total Neoadjuvant Therapy in pMMR/MSS](https://onco.cc/trials/nct07005570/), [Short-course Radiotherapy in TNT Combined With Enlonstobart for pMMR LARC](https://onco.cc/trials/nct07448077/), [Short-Course Radiotherapy With Tumor-Draining Lymph Node Preservation Followed by PD-1 Inhibitors in pMMR/MSS Stage II-III Rectal Cancer](https://onco.cc/trials/nct07394192/), [Short-Course Radiotherapy, Nal-IRI, Capecitabine, and Camrelizumab for Locally Advanced MSS Rectal Cancer](https://onco.cc/trials/nct07521605/), [Short-course RT Followed by NALIRIFOX Plus Pucotenlimab as Neoadjuvant Therapy for High-risk Locally Advanced Rectal Cancer With MSS/pMMR](https://onco.cc/trials/nct07651007/), [Short-Course RT Plus CAPOX and Tislelizumab vs Long-Course CRT Plus Tislelizumab for Locally Advanced Rectal Cancer](https://onco.cc/trials/nct07469306/), [SHR-1701 Combined with SHR2554 and BP102 for MCRC](https://onco.cc/trials/nct06679673/), [SHR-3821 in Advanced Colorectal Cancer: an Exploratory Study](https://onco.cc/trials/nct07515820/), [SHR-8068 Combined With Adbelizumab and BP102 in the Treatment of Advanced Colorectal Cancer](https://onco.cc/trials/nct06373133/), [SHR-A1811 Combined with Apatinib in the Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma and Colorectal Cancer](https://onco.cc/trials/nct06666166/), [SHR-A1904 in Advanced Colorectal Cancer: an Exploratory Study](https://onco.cc/trials/nct07700719/), [SIB-RT Combined With CAPOX and PD-1 for High-Risk Rectal Cancer](https://onco.cc/trials/nct07297030/), [Simultaneous Boost in Neoadjuvant Radiotherapy for Rectal Cancer](https://onco.cc/trials/nct07200141/), [Single Arm Study of Neoadjuvant Dostarlimab in Stage II and III Deficient Mismatch Repair Colon Cancers](https://onco.cc/trials/nct05239546/), [Single cEll pRofiling PErsistaNce To ImmuNothErapy](https://onco.cc/trials/nct06680739/), [Single-arm, Phase II Clinical Study Evaluating the Safety and Efficacy of Sintilimab Combined With IBI-310 and Chemotherapy as Neoadjuvant Therapy for Locally A](https://onco.cc/trials/nct07750951/), [Sintilimab in Combination with Cetuximab and Chemotherapy As First-line Treatment for RAS/BRAF Wild-type Advanced Colorectal Cancer](https://onco.cc/trials/nct06776757/), [Sintilimab Plus Bevacizumab and Chemotherapy in MSS/pMMR Colorectal With no Liver Metastasis](https://onco.cc/trials/nct06973343/), [Sintilimab Plus Gossypol Acetate in Advanced Colorectal Cancer](https://onco.cc/trials/nct07656766/), [Standard Dose Versus High Dose of Radiotherapy in Rectal Preservation With Chemo-radiotherapy in Rectal Cancer Patients](https://onco.cc/trials/nct04095299/), [Standard Second-line Therapy With ONgericimab and TOripalimab in pMMR/MSS Colorectal Cancer: a Single-arm Phase II Trial](https://onco.cc/trials/nct07106034/), [Standard Systemic Therapy Combined With High/Low-dose Radiotherapy Plus Toripalimab for Metastatic Colorectal Cancer](https://onco.cc/trials/nct06525428/), [Stereotactic Ablative Radiotherapy (SABR) for the Treatment of Patients With Metastatic Cancer, ID-COMET Trial](https://onco.cc/trials/nct06563388/), [Stereotactic Body Radiation Therapy (SBRT) for Unresectable Liver Metastases](https://onco.cc/trials/nct02185443/), [Stereotactic Body Radiation Therapy for Unresectable Locally Recurrent Rectal Cancer](https://onco.cc/trials/nct07297004/), [Stereotactic Brain-directed Radiation With or Without Aguix Gadolinium-Based Nanoparticles in Brain Metastases](https://onco.cc/trials/nct04899908/), [STREAM-2: Second-line Treatment With REgorafenib in Advanced RAS-Mutant Colorectal Cancer](https://onco.cc/trials/nct07213570/), [Study Evaluating the Tailored Management of Locally-advanced Rectal Carcinoma](https://onco.cc/trials/nct04749108/), [Study Evaluating Two Treatment Strategies for Rectal Cancer in Patients ≥75 Years Old](https://onco.cc/trials/nct07118800/), [Study in mCRC Patients RAS/BRAF wt Tissue and RAS Mutated LIquid BIopsy to Compare FOLFIRI Plus CetuxiMAb or BevacizumaB](https://onco.cc/trials/nct04776655/), [Study of Folfiri/Cetuximab in FcGammaRIIIa V/V Stage IV Colorectal Cancer Patients](https://onco.cc/trials/nct03874026/), [Study of Fruquintinib Combined With Tegafur Gimeracil Oteracil in Patients With Metastatic Colorectal Cancer](https://onco.cc/trials/nct06255379/), [Study of Safety/Feasibility of a Hybrid Model of Tertiary and Community Delivery of Hepatic Artery Infusion Chemotherapy](https://onco.cc/trials/nct07201519/), [Study on Aspirin Versus Placebo in Resected Colon Cancer With PI3K Mutation Stage III or II High Risk](https://onco.cc/trials/nct02945033/), [Study on the Efficacy and Safety of Neoadjuvant Radiotherapy Combined With Tislelizumab, Liposomal Irinotecan, and Capecitabine in the Treatment of pMMR Locally](https://onco.cc/trials/nct07104604/), [Study to Evaluate the Efficacy and Safety of Cetuximab in Combination with Encorafenib Plus Binimetinib As Induction Treatment in BRAF V600E Mutated MSS Initial](https://onco.cc/trials/nct06207656/), [Study to Evaluate the Efficacy of FOLFOX + Panitumumab Followed by FOLFIRI + Bevacizumab (Sequence 1) Versus FOLFOX + Bevacizumab Followed by FOLFIRI + Panitumu](https://onco.cc/trials/nct03635021/), [Study to Evaluate the Use of Capecitabine in Monotherapy and in Combination With Oxaliplatin in Elderly Patients as Adjuvant Chemotherapy for Locally Advanced C](https://onco.cc/trials/nct06888843/), [Sulfasalazine in Patients With Metastatic Colorectal Cancer](https://onco.cc/trials/nct06134388/), [Surgery Plus Chemo Versus Chemoradiotherapy Followed by Surgery Plus Chemo for Locally Recurrent Rectal Cancer](https://onco.cc/trials/nct04288999/), [Systemic Antitumor Treatment with or Without Pressurized Intraperitoneal Aerosol Chemotherapy for Colon Peritoneal Metastases (PIPOX02)](https://onco.cc/trials/nct06681038/), [Systemic Oxaliplatin or Intra-arterial Chemotherapy Combined With LV5FU2 +/- Irinotecan and an Target Therapy in First Line Treatment of Metastatic Colorectal C](https://onco.cc/trials/nct02885753/), [TAS-102 Combined With Bevacizumab for Second-line Maintenance Treatment of Advanced Colorectal Cancer](https://onco.cc/trials/nct06293014/), [TAS-102 With or Without Celecoxib in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant Chemotherapy](https://onco.cc/trials/nct05343013/), [Technical Feasibility of Modified Early Post-Operative Intraperitoneal Chemotherapy (mEPIC)](https://onco.cc/trials/nct05913674/), [Telehealth Intervention for Ostomy Self-Management](https://onco.cc/trials/nct06528990/), [Testing a Functional Precision Medicine Approach to Select Chemotherapy for Metastatic Colorectal Cancer (COSENSE-1)](https://onco.cc/trials/nct06907342/), [Testing Ivonescimab in Combination With Chemotherapy in Patients With Metastatic Colorectal Cancers Without Liver Metastases](https://onco.cc/trials/nct07359456/), [Testing the Addition of an Anti-Cancer Drug, Irinotecan, to the Standard Chemotherapy Treatment (FOLFOX) After Long-Course Radiation Therapy for Advanced-Stage](https://onco.cc/trials/nct05610163/), [Testing the Addition of Atezolizumab to Combination Chemotherapy or Atezolizumab Alone for Metastatic Colon or Rectal Cancer, the COMMIT Study](https://onco.cc/trials/nct02997228/), [Testing the Addition of Total Ablative Therapy to Usual Systemic Therapy Treatment for Limited Metastatic Colorectal Cancer, ERASur Trial](https://onco.cc/trials/nct05673148/), [Testing the Combination of Anti-Cancer Drugs, Botensilimab (AGEN1181) and Balstilimab (AGEN2034), After Standard Treatment for Colorectal Cancer, Combat Trial](https://onco.cc/trials/nct07551596/), [Testing the Combination of the Anti-Cancer Drugs Temozolomide and M1774 to Evaluate Their Safety and Effectiveness](https://onco.cc/trials/nct05691491/), [Testing the Effectiveness of the Anti-cancer Drug Pidnarulex (CX-5461), in Combination With Another Anti-cancer Drug Cemiplimab (REGN2810), in Treating Refracto](https://onco.cc/trials/nct07147231/), [Testing the Use of BRAF-Targeted Therapy After Surgery and Usual Chemotherapy for BRAF-Mutated Colon Cancer](https://onco.cc/trials/nct05710406/), [Thalidomide Enhances Clinical Efficacy of Cetuximab Combined With Standard Chemotherapy for Left Colorectal Cancer](https://onco.cc/trials/nct06279351/), [The Aim of This Study is to Assess the Efficacy and Safety of Chidamide, Regorafenib in Combination With Iparomlimab and Tuvonralimab for the Treatment of Advan](https://onco.cc/trials/nct06930118/), [The Combination of Hypofractionated Radiotherapy and Immunotherapy in Locally Recurrent Rectal Cancer](https://onco.cc/trials/nct05628038/), [The Combination of Immunotherapy and Neoadjuvant Short-course Radiotherapy in Early Rectal Cancer](https://onco.cc/trials/nct05555888/), [The Effects of Neoadjuvant Tislelizumab Combined With Chemotherapy in Locally Advanced MSS Rectal Cancer](https://onco.cc/trials/nct06254521/), [The Efficacy and Safety of IBI351, Cetuximab β Combined With FOLFIRI as First-line /IBI351, Cetuximab β as Second-line in the Treatment of KRAS G12C-mutated Met](https://onco.cc/trials/nct06959589/), [The Efficacy and Safety of Short-course Radiation Combined With Adebrelimab and CAPEOX Neo-adjuvant Therapy for Organ-retention in Patients With MSS/pMMR Ultra](https://onco.cc/trials/nct06266832/), [The Efficacy and Safety of TAS-102(Suyuan) Combined With Bevacizumab as First-line Therapy in Patients With Advanced Colorectal Cancer](https://onco.cc/trials/nct06092242/), [The Efficacy of Primary Total Mesorectal Excision (TME) Surgery Versus Neoadjuvant Chemotherapy Combined With TME Surgery in Low-risk Locally Advanced Rectal Ca](https://onco.cc/trials/nct05984485/), [The Impact of a Patient Decision Aid on Treatment Choices for Patients With an Unexpected Malignant Colorectal Polyp](https://onco.cc/trials/nct05776381/), [The Phase 1b/IIa, Open-label, Dose Escalation and Dose Expansion to Evaluate Safety, Tolerability, and Preliminary Efficacy of the Combination of HCB101, Cetuxi](https://onco.cc/trials/nct07204574/), [The Possible Protective Role of Ketotifen Against Oxaliplatin Induced Peripheral Neuropathy](https://onco.cc/trials/nct05624138/), [The Safety and Efficacy of Cetuximab Beta Plus Fruquintinib With or Without Immune Checkpoint Inhibitorrs in First-line Treatment of RAS/BRAF Wild Type Unresect](https://onco.cc/trials/nct07257653/), [The Sagittarius Trial](https://onco.cc/trials/nct06490536/), [The Study of JMT101 Combined With Irinotecan as a ≥3rd-Line Treatment in Metastatic Colorectal Cancer](https://onco.cc/trials/nct07134205/), [The Use of Indocyanine Green Near-infrared Fluorescence for Bowel Perfusion Quantitative Assessment in Order to Prevent Anastomotic Leakage in Colorectal Surger](https://onco.cc/trials/nct06845306/), [Thymosin-alpha 1 for Adjuvant Treatment After Radical Resection of High-risk Stage II and III Colorectal Cancer](https://onco.cc/trials/nct05086614/), [Tislelizumab Combined With Chemotherapy (CAPOX) in the Perioperative Treatment of MSI-H/dMMR Stage II or III Colorectal Cancer](https://onco.cc/trials/nct05841134/), [Tislelizumab in People With Colorectal Cancer](https://onco.cc/trials/nct06529523/), [TNT of SCRT+CAPOX vs SCRT+CAPOXIRI for Locally Advanced Rectal Cancer](https://onco.cc/trials/nct05646511/), [To Explore the Efficacy of Sintilimab Combined With Bevacizumab in Rectal Cancer](https://onco.cc/trials/nct06808412/), [Tolecizumab Plus Chemoimmunotherapy for pMMR/MSS Locally Advanced Colon Adenocarcinoma](https://onco.cc/trials/nct07468630/), [Toripalimab Plus Celecoxib for dMMR/MSI-H Locally Advanced Colorectal Cancer](https://onco.cc/trials/nct06903858/), [Total Neoadjuvant Chemoradiotherapy Plus Anti-PD-1 in Subperitoneal Patients With Locally Advanced Rectal CancerPatients With Locally Advanced Rectal Cancer: A](https://onco.cc/trials/nct05998122/), [Total Neoadjuvant mFOLFOX6 Plus Suvemcitug and Enlonstobart With Selective Omission of Pelvic Radiotherapy for High-Risk Mid-Rectal Locally Advanced Rectal Canc](https://onco.cc/trials/nct07810114/), [Total Neoadjuvant Therapy and Organ Preservation Versus Surgery for Rectal Cancer.](https://onco.cc/trials/nct06758830/), [Total Neoadjuvant Therapy in Rectal Cancer](https://onco.cc/trials/nct06162650/), [Total Neoadjuvant Therapy With mFOLFOX and Short-course Radiation in Resectable Rectal Cancer](https://onco.cc/trials/nct04643366/), [Total Neoadjuvant Therapy With PD-1 for Locally Advcancer Rectal Cancer](https://onco.cc/trials/nct07214142/), [Total Neoadjuvant Treatment ±Immunotherapy for High Risk Locally Advanced Rectal Cancer (TNTi)](https://onco.cc/trials/nct06229041/), [Total Neoadjuvant Treatment for pMMR Locally Advanced Low Rectal Cancer: Anti-PD-1 Antibody With FOLFOXIRI and Preoperative Radiation Therapy](https://onco.cc/trials/nct06099951/), [Total Neoadjuvant Treatment With or Without Tislelizumab for Locally Advanced Rectal Cancer.](https://onco.cc/trials/nct06940388/), [Tovecimig Plus FOLFIRI in Second Line Metastatic Colorectal Cancer](https://onco.cc/trials/nct07662031/), [Treating Locally Advanced Rectal Cancer With TAS-102 Chemotherapy Plus Neoadjuvant Radiotherapy](https://onco.cc/trials/nct05965531/), [Treatment of Rectal Cancer With Long-term Concurrent Chemoradiotherapy Combined With Camrelizumab](https://onco.cc/trials/nct06304545/), [Trial of 5-Fluorouracil (5FU)-Based Therapy in Combination With Fruquintinib in Patients With Locally Advanced Unresectable or Metastatic Colorectal Cancer](https://onco.cc/trials/nct07042685/), [Trial of AMB-05X for Patients With ctDNA(+) Colorectal Cancer After Curative-intent Treatment](https://onco.cc/trials/nct06617858/), [Trial of Gum Chewing to Enhance the Restoration of Intestinal Motility in Colorectal Cancer Surgery](https://onco.cc/trials/nct06860685/), [Trial of the Efficacy and Safety of Short and Long Course Radiation Therapy With/Without BMX-001](https://onco.cc/trials/nct05254327/), [Trial Utilizing Metronidazole to Optimize the Microbiome of Rectal Adenocarcinoma Undergoing Neoadjuvant Therapy](https://onco.cc/trials/nct06569368/), [Trifluridine/ Tipiracil Plus Panitumumab Versus Trifluridine/ Tipiracil Plus Bevacizumab as First-line Treatment of Metastatic Colorectal Cancer](https://onco.cc/trials/nct05007132/), [Trifluridine/Tipiracil Plus Fruquintinib vs. Trifluridine/Tipiracil Plus Bevacizumab in Refractory Metastatic Colorectal Cancer: A Randomized, Controlled, Open-](https://onco.cc/trials/nct07261709/), [Trifluridine/Tipiracil Plus Regorafenib vs Trifluridine/Tipiracil Plus Bevacizumab for Refractory Metastatic Colorectal Cancer](https://onco.cc/trials/nct06992648/), [Triplet Combination or Doublet Regimen Versus Chemoradiation as Neoadjuvant Therapy for Locally Advanced Rectal Cancer](https://onco.cc/trials/nct03975049/), [Tumor Local Excision +Postoperative Adjuvant Chemoradiotherapy for T1-2N0M0 Low/Ultra-Low Rectal Cancer](https://onco.cc/trials/nct06949098/), [Umbrella Trial of Neoadjuvant Therapy for Locally Advanced Colorectal Cancer](https://onco.cc/trials/nct07503639/), [Upfront Trastuzumab-Deruxtecan Plus Capecitabine and Bevacizumab for Patients With HER-2 Positive Metastatic Colorectal Cancer.](https://onco.cc/trials/nct07407465/), [Vaccination with Autologous Dendritic Cells Loaded with Autologous Tumour Homogenate After Curative Resection for Stage IV Colorectal Cancer.](https://onco.cc/trials/nct02919644/), [Vaginal DHEA to Improve Vaginal Health After Radiation for Women With Gynecologic, Anal or Rectal Cancer](https://onco.cc/trials/nct07407647/), [ValproIc Acid to Potentiate Anti-EGFR Treatment Efficacy and Prevent/Revert Resistance in Colorectal Cancer](https://onco.cc/trials/nct06714357/), [Vitamin D3 With Chemotherapy and Bevacizumab in Treating Patients With Advanced or Metastatic Colorectal Cancer](https://onco.cc/trials/nct04094688/), [Vitamin E Combined With Fruquintinib and Tislelizumab in Microsatellite Stabilized Metastatic Colorectal Cancer Patients](https://onco.cc/trials/nct05771181/), [XELOX Plus DoSTARlimab Versus XELOX Alone as Consolidation Treatment After Standard Chemoradiation in pMMR/MSS or MSI-Low Locally Advanced Rectal Cancer (LARC)](https://onco.cc/trials/nct07381777/), [XP-102 and XP-102 in Combination With Trametinib in Advanced Solid Tumor Patients With a BRAF V600 Mutation](https://onco.cc/trials/nct05275374/), [XS-03 in Combination With FOLFOX or FOLFIRI and Bevacizumab for Treatment of Metastatic Colorectal Cancer Patients With RAS Mutation](https://onco.cc/trials/nct06936527/), [Y-90, Capecitabine, and Atezolizumab for Oligometastatic CRC](https://onco.cc/trials/nct06555133/), [Yang et al. Anti-PD-1/CTLA-4 Dual Immunotherapy for LARC](https://onco.cc/trials/nct07596290/), [Zanidatamab Before Surgery for the Treatment of HER2 Positive Colon and Rectal Cancer in Patients Planned for Curative Intent Treatment](https://onco.cc/trials/nct07405476/), [Zanzalintinib Alone or in Combination With Pembrolizumab and Berahyaluronidase Alfa in Participants With Colorectal Cancer With Molecular Residual Disease](https://onco.cc/trials/nct07750158/)

---
JSON: https://onco.cc/api/v1/entities/colorectal-trials-open-today.json